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vABSTRACT
Huntington’s disease (HD) is a mid-life-onset neurodegenerative disorder
characterized by involuntary movements, personality changes and dementia. It progresses to
death within 10-20 years after onset. There is currently no cure to treat this fatal disease. In
HD patients, the protein huntingtin contains an abnormal expansion of a polyglutamine tract,
which leads to the selective death of striatal neurons. The functions of huntingtin, as well as
the dysfunctions induced by the mutation are still poorly understood
The first chapter of this thesis describes the state of the art in the study of
Huntington’s disease: huntingtin (htt), the protein which induces the disease; the hypothesis
of toxic pathways induced by the mutant htt and the proposed therapeutic strategies to
interfere with them; the available cellular and animal models and finally; the promise of gene
therapy for neurodegenerative diseases such as Huntington’s disease.
The second chapter presents a new cellular model of the developed by infecting
primary cultures with lentiviral vectors expressing a mutant htt fragment. This model is
characterized by generalized neuronal transgene chronic pathology, expression, neuronal
dysfunction and finally cell death. The slow progression in this model allows the study of the
cascade of events leading to cell death. These unique characteristics allow the investigation of
the pathological events induced by htt expression with analytical techniques on the entire
neuronal population. The chapter ends with the description of an experiment showing the
neuroprotective effects of ciliary neurotrophic factor (CNTF) and brain-derived neurotrophic
factor (BDNF) on thiese neurons.
 The third chapter describes the delivery of CNTF in transgenic HD mice which
express the human full-length htt (YAC72). CNTF was delivered directly to the affected
neurons by striatal lentiviral injection. The sustained one-year delivery was not associated
with side effects; it was correlated to reduced hyperactivity and a reduction in degenerating
neurons. However, a neuroprotective effect was difficult to establish, due to the very mild and
subtle pathology occurring in these animals.
The fourth chapter considers delivery of BDNF in two genetic rodent HD models: in
the mild phenotypic HD mice (YAC128) and a more severe rat model based on the lentiviral
delivery of mutant htt in the striatum. No neuroprotective effect of BDNF could be detected in
either animal model.
The conclusions of this thesis discuss the potential of lentiviral vectors in modeling
neurodegenerative diseases in vitro and in vivo, as well as their potential role in the treatment
vi
of such diseases. The perspective gained by the developed cellular model toward the
understanding of the molecular events induced by mutant huntingtin is discussed, as well as
the difficulties in testing neuroprotective approaches on animal models of HD.
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RIASSUNTO
La corea di Huntington (HD) è una malattia genetica neurodegenerativa caratterizzata
da movimenti involontari, cambiamenti di personalità e da demenza. La malattia progredisce
fino alla morte del paziente, da 10 a 20 anni dopo la manifestazione dei primi sintomi. Non
esiste nessuna cura in grado di arrestare o rallentare il corso della malattia. Nei pazienti affetti
da HD, la proteina huntintina contiene un’espansione anormale di una ripetizione di
poliglutamine che induce la morte neuronale dei neuroni dello striato. Le funzioni
dell’huntintina e le disfunzioni indotte dalla mutazione sono ancora sconosciute.
Il primo capitolo descrive lo stato attuale della ricerca sulla corea di Huntington, la
proteina coinvolta nella malattia: la huntintina mutata; le ipotesi sui meccanismi della sua
tossicità e le possibilità terapeutiche, seguono i modelli cellulari e animali disponibili ed
infine le possibilità di terapia genica per delle malattie neurodegenerative.
Il secondo capitolo descrive un nuovo modello cellulare ottenuto infettando delle
culture primarie striatali con dei vettori lentivirali che esprimono un frammento della
huntintina mutata. Questo modello è caratterizzato da una patologia cronica, un’espressione
generalizzata a tutti i neuroni e da una disfunzione seguita da morte neuronale. Queste
caratteristiche proprie al nuovo modello lo rendono idoneo allo studio della patologia con
tecniche analitiche su tutta la popolazione neuronale, non più limitate a singole osservazioni
cellulari. In oltre, la sua progressione rende possibile discernere la sequenza dei differenti
avvenimenti. Il capitolo termina mostrando come questi neuroni destinati alla morte possono
essere salvati da due fattori neurotrofici, il CNTF ed il BDNF.
Il terzo capitolo descrive la somministrazione di CNTF in topi transgenici YAC72, i
quali esprimono l’huntintina umana mutata in tutta la sua lunghezza. Abbiamo dunque
iniettato direttamente nello striato di topi transgenici il vettore lentivirale CNTF.
L’espressione di CNTF costante per almeno un anno, non è stata correlata da effetti
collaterali, ma ha cambiato l’attività locomotrice dei topi rendendoli meno iperattivi. Lo
studio istologico ha dimostrato che il numero di neuroni in degenerazione è ridotto alla metà.
Purtroppo l’effetto protettivo non si è potuto provare dato l’esiguo numero di casi di morte
neuronale.
Il quarto capitolo descrive un esperimento analogo: il BDNF è stato amministrato in
topi transgenici YAC128. Questi topi avrebbero dovuto manifestare una patologia più acuta
dei topi utilizzati in precedenza. Le stesse difficoltà legate alla mancanza di patologia
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neuronale ci hanno impedito di determinare l’efficienza del BDNF. Abbiamo dunque
utilizzato un modello molto più severo, l’espressione di un frammento della huntintina mutata
tramite vettori lentivirali nello striato di ratti, infatti il BDNF non è neuroprotettore in questo
paradigma sperimentale.
La conclusione di questa tesi di ricerca discute la capacità dei vettori lentivirali di
modellare in vitro ed in vivo le malattie neurodegenerative e la loro potenzialità per curare le
stesse malattie. I risultati insoddisfacenti ottenuti sui modelli animali inducono a sviluppare
nuovi paradigmi sperimentali per verificare le potenzialità di fattori terapeutici non soltanto su
modelli cellulari ma anche animali.
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11. INTRODUCTION
The central nervous system (CNS) is the most complex, amazing and still mysterious
structure of our body, controlling functions such as voluntary movements and perception, but
also learning, creativity, abstract thinking and emotions. Multiple pathways are orchestrating
these functions in networks of highly specialized neurons. Evolution has provided a robust
skull and backbone to protect the CNS from outside mechanical injuries, and a molecular
obstacle, the blood-brain barrier, to protect it from endogenous chemical agents. However, the
brain is still vulnerable, as revealed by the emergence of neurodegenerative diseases
associated with dramatic increases in human live expectancy. Dysfunctions in this complex
system can lead to a wide range of different severe pathologies such as Alzheimer’s,
Parkinson’s, Amyotrophic Lateral Sclerosis or Huntington’s disease. These disorders are
characterized by a specific degeneration of neurons in well-defined areas of the CNS. The
molecular bases of these specific neuronal losses are not yet fully understood, but major
medical research efforts are concentrated on finding therapies to slow down or stop the course
of these disorders.
Cellular and animal models have been developed to mimic these complex pathologies.
Models faithfully reproducing a human disease are indispensable tools to analyze, understand,
and finally, test interventions against the disorder. This helps explain the great research
interest in Huntington’s disease (HD). Although it is rare compared to Parkinson’s and
Alzheimer’s, it is the paradigm of a dominant monogenetic disease. The genetic factor,
underlying HD was identified in 1993 as a mutation in a unknown protein: a polyglutamine
expansion in huntingtin. This is the primary cause of neuronal dysfunction, accumulation of
insoluble proteins and neuronal death, which are events common to most of chronic
neurodegenerative diseases. With the technological advances in molecular biology and gene
transfer techniques, mutant huntingtin can be delivered to living cells to model HD in cell
cultures but also in animals. These genetic models are important tools to understand the toxic
mechanisms leading to neuronal death, as well as to test therapeutic approaches.
The first goal of this thesis was to develop a cellular genetic model for Huntington’s disease,
closely mimicking the typical features of the pathology which can be used for fundamental
research as well as a platform to develop potential therapies. This goal was strongly inspired
2by the seminal paper of Saudou et. al. in 1998, which described a new cellular model by
transfecting a mutant huntingtin fragment in primary striatal neurons. In that model, neurons
experience similar chronic molecular events and death as is observed in the human pathology.
The fast kinetics and the scarce transfection yield limit the analysis of pathological events to
single cell analysis. To overcome this disadvantage, we used a lentiviral vector, which can
efficiently infect non-dividing cells such as neurons and therefore increase the neuronal
population expressing mutant htt. The elegant, slow kinetics of the pathological events
leading to neuronal death, combined with a generalized neuronal transgene expression are
unique features of this cellular paradigm which allow the analysis of population dysfunctions
at different time points and open new avenues to understanding the impact of mutant htt.
The second goal of this thesis was the evaluation of therapeutic strategies, first in the new
cellular model, then in genetic animal models. Neurotrophic factors have been proposed to
slow down, or arrest disease progression or even promote regeneration in neurodegenerative
diseases. CNTF and BDNF have shown a specially strong protection spectrum in different
paradigms of striatal neuron injuries, both in vitro and in vivo. We have therefore tested if the
lentiviral mediated delivery of these factors could represent an efficient treatment for HD.
Complete rescue from neuronal death in vitro and long-term delivery of trophic factors in vivo
without any side effects are encouraging with regard to both gene therapy and the possible
beneficial effects of these trophic factors.
31.1. HUNTINGTON’S DISEASE
1.1.1. Eponym Huntington: introduction to the disease
Huntington’s disease is a fatal neurodegenerative disease named after George Summer
Huntington (Figure 1) who first described the disorder in 1872 (Huntington, 2003). His
original paper published under the title “ On Chorea” is brief, complete and still up-to-date in
major aspects. Going through Huntington’s publication represents an excellent introduction to
the disorder.
Figure 1: Photograph of George Summer Huntington
Born 1850, East Hampton, New York, USA –1916, died in Cairo, New York, USA (Okun, 2003).
Inheritance
‘When either or both the parents have shown manifestations of the disease,
and more especially when these manifestations have been of a serious nature,
one or more of the offspring almost invariably suffer from the disease if they
live to adult age. But if by any chance these children go through life without
it, the thread is broken and the grandchildren and the great-grandchildren of
the original shakers may rest assured that they are free from the disease.’
This description of the autosomal dominant trait of the mutation is remarkable, because the
knowledge of genetics was poorly integrated by the scientific community at that time and
Mendel’s Laws describing the principle of hereditary transmission were still largely ignored,
4although they had been published seven years before in 1865 in a book under the title
Versuche über Pflanzen-hybride (Treaties on Plant Hybrids). These theories were
rediscovered in the early 20th century, when the cell and chromosome structures were
better understood, and significant interest for HD, especially its hereditary aspect, was
stimulated by Huntington’s paper.
Dementia
‘The tendency to insanity, and sometimes that form of insanity which leads to
suicide, is marked. I know of several instances of suicide of people suffering
from this form of chorea, or who belonged to families in which the disease
existed. As the disease progresses the mind becomes more or less impaired, in
many amounting to insanity, while in others both mind and body gradually
fail until death relieves them of their sufferings. At present I know of two
married men, whose wives are living, and who are constantly making love to
some young lady, not seeming to be aware that there is any impropriety in it.
They are suffering from chorea to such an extent that they can hardly walk,
and would be thought, by a stranger, to be intoxicated. They are men of about
fifty years of age, but never let an opportunity to flirt with a girl go past
unimproved. The effect is ridiculous in the extreme’.
A second aspect of the hereditary chorea he observed is dementia and depression. Mood and
behavioral disturbance, memory impairment and personality changes are typical clinical
features of the disorder, occurring in general before the onset of chorea. Indeed, suicide
attempts are more frequent in persons carrying the HD mutation. These secondary treats of
the disorder are often ignored as they are less impressive than the abrupt motor dysfunctions
and can only be perceived by relatives living close to HD patients. Antidepressant and
antipsychotic drugs are often being prescribed to HD patients.
Adult onset
‘Its third peculiarity is its coming on, at least as a grave disease, only in
adult life. I do not know of a single case that has shown any marked signs of
chorea before the age of thirty or forty years, while those who pass the
fortieth year without symptoms of the disease are seldom attacked.’
5Huntington’s disease is predominantly an adult disorder, with the average onset between 35
and 42 years (Quinn and Schrag, 1998). However, the disease can start at any age and 6% are
juvenile forms, with an onset before the age of 20 (Figure 2). These early onsets have quite a
different clinical description with the absence of abrupt movements and chorea. As it will be
discussed in chapter 1.2.2 the age of onset is closely correlated with the extent of the mutation
in the huntingtin gene.
Figure 2: Proportion of HD subjects living and deceased
Data are from a sample of 2492 patients, collected as part of the National research Roster for Huntington (Foroud
et al., 1999)
Movement disorders
It begins as an ordinary chorea might begin, by the irregular and spasmodic
action of certain muscles, as of the face, arms, etc. These movements
gradually increase, when muscles hitherto unaffected take on the spasmodic
action, until every muscle in the body becomes affected (excepting the
involuntary ones), and the poor patient presents a spectacle, which is
anything but pleasing to witness. I have never known a recovery or even an
amelioration of symptoms in this form of chorea; when once it begins it
clings to the bitter end. No treatment seems to be of any avail, and indeed
nowadays its end is so well known to the sufferer and his friends, that
medical advice is seldom sought. It seems at least to be one of the
incurables’.
6These uncontrolled and involuntary movements are the most peculiar trait of the disorder.
They were probably the cause for the famous witch trials in Salem, Massachusetts in 1692,
where several girls were judged and executed as witches possessed by the devil (Trask, 1997).
George Huntington concluded his essay with the sad statement that no cure is available and
that the death of the affected persons is inevitable. More than a century after Huntington’s
paper, and more than ten years after the discovery of the HD gene, still no effective treatment
is available and the disease progresses uninterrupted to the death of the patient.
1.1.2. Epidemiology of HD and the discovery of huntingtin
Huntington’s disease is the most prevalent disorder in a family of nine neurodegenerative
diseases that are caused by a polyglutamine expansion in the associated proteins. HD affects
both sexes with the same frequency. The highest prevalence is in Europe and North America,
with 4-8 cases per 100’000 (Squitieri et al., 1994). In Switzerland about 400 persons are
affected by the disorder (Laccone et al., 1999). HD is notably rare in Finland and in Japan
(Harper, 1992). An extremely high occurrence was found within the 15’000 members of a
large group of inter-related families living in fishing villages along the borders of Lake
Maracaibo in Venezuela (Negrette, 1955). The common ancestor of these families was a
woman with el mal de San Vito, as the locals named Huntington’s disease, who had 10
children about 200 years ago. This sad peculiarity led to the foundation of the Venezuela
Huntington’s disease project with Nancy Wexler as principal investigator. The aim of that
project was to identify the chromosomal region, and ultimately the gene, responsible for HD.
These big families were therefore genetically screened, and in 1983 a transcript called IT15
(interesting transcript 15) located on the 4th chromosome was shown to be associated with the
disease (Gusella et al., 1983). This was the first gene linked to a disease to be mapped. Ten
years later, in 1993, the gene was finally isolated and called the HD gene or huntingtin (htt)
(The Huntington's Disease Collaborative Research Group, 1993). The mutation leading to HD
was identified as a polyglutamine expansion in the N-terminal region of the protein. The
discovery of htt was a major breakthrough for HD research allowing the development of
genetic models both in vitro and in vivo, and also opened the possibility to perform genetic
screening for the mutation on individuals at risk, including human fetuses or even for in vitro
fertilized eggs prior to implantation.
71.1.3. Clinical aspects of HD
Huntington’s disease is a progressive neurodegenerative disorder characterized by chorea
(which means dance in Greek) rigidity and dementia; moreover its juvenile form is frequently
associated with seizures. This chapter describes the typical decline of an HD patient from the
onset until death.
Psychiatric symptoms are believed to occur before the development of neurological
symptoms, but a study performed by Shiwach and Norbury concluded that asymptomatic HD
gene carriers do not have a greater incidence of psychiatric disorders than non-gene carriers
born from a HD parent (Shiwach and Norbury, 1994). However, what the study revealed is
that at-risk persons have often psychiatric episodes, probably associated with the uncertainty
of having inherited the mutation. The authors conclude that neither depression nor psychiatric
disorders are significant pre-neurological indicators of the disease. In contrast to this,
attention, learning and planning are affected even before the onset of clinical symptoms
(Rosenberg et al., 1995).
The definition of onset is often unclear and imprecise. A common definition is the time of the
first appearance of persistent motor abnormalities, which can be of different nature. Ocular
motor abnormalities, especially the saccadic movement, are observed in early HD and are
often tested to assess the onset of the disease (Berardelli et al., 1999).
The initial symptoms vary from person to person. In general, involuntary movements of face,
fingers, feet or thorax manifest the onset. Symptoms develop gradually and are initially very
subtle and hard to detect, as they only weakly influence the normal life of the affected person,
who keeps his independence. In concomitance, abrupt mood changes, unusual apathy,
irritability, anger and depression are commonly observed. Minor motor abnormalities usually
precede the obvious signs of dysfunction, which follow at least 3 years later (Folstein et al.,
1986; Penney et al., 1990).
As HD progresses, the physical, intellectual and emotional symptoms become more marked.
In many cases, the affected person develops overt choreiform movements of the head, neck,
arms and legs. These characteristic movements are present in 90 percent of patients. In
juvenile forms, the patient will often experience muscle rigidity and bradykinesia without
chorea. This form of the disease is also called ‘Westphal variant’ of HD and affects 6% of HD
patients (Hayden et al., 1981; Gervais et al., 2002; Zackowski et al., 2002). Weight loss is one
of the features of advanced HD and is not related to a poor dietary intake (Morales et al.,
1989).
8Bradykinesia, rigidity and dystonia gradually appear and often dominate the final stage of the
disease, in which the patient will become severely rigid, grossly akinetic and dysphagic.
About 20 percent are incontinent. A global decline in cognitive capabilities is present at the
final stage. Due to severe dementia and progressive motor dysfunction, patients with
advanced HD may become unable to walk, have poor dietary intake, eventually cease to talk,
and become unable to care for themselves, potentially requiring long-term institutional care.
Fatal complications may result from injuries related to serious falls, poor nutrition, infection,
choking, inflammation of the lungs and heart failure (http://www.wemove.org).
1.1.4. The neuropathology of HD
The neurodegenerative process starts in the striatum, which is so called because of its striped
structure (Figure 3). More than 95% of striatal neurons are medium spiny projecting neurons
(MSN), which use gamma-aminobutyric acid (GABA) as their primary inhibitory
neurotransmitter (Chesselet and Delfs, 1996). These neurons are most severely affected,
resulting in atrophy of the striatum, first in the caudate nucleus, then in the putamen. Post-
mortem brains of advanced state HD patients are recognized by the dilatation of the lateral
ventricles due to striatal shrinkage. Glial proliferation is observed in concomitance with
neuronal cell loss (Robitaille et al., 1997).
The first degenerating subpopulation of striatal neurons belongs to the so-called ‘indirect’
pathway (see chapter 1.1.5). These neurons express enkephalin and are enriched in dopamine
receptor D2 (Reiner et al., 1988; Albin et al., 1991; Richfield et al., 1995; Sapp et al., 1995).
In contrast, striatal interneurons, including large spiny cholinergic cells, medium aspiny
neurons as well as somatostatin-, neuropeptide Y-, nitric oxide synthase (NOD)- and
parvalbumin positive neurons are spared (Ferrante et al., 1985; Graveland et al., 1985;
Ferrante et al., 1987a; Ferrante et al., 1987b; Sieradzan and Mann, 2001). The neuronal loss in
the cortex is less severe. Large neurons in layer V and VI, which project to the striatum, are
mostly affected (Hedreen et al., 1991).
Vonsattel et al. have proposed a system for grading the severity of neuropathology by
macroscopic and microscopic criteria (Vonsattel et al., 1985). The grades correlate closely
with the extent of clinical disability and are ranking from grade 0 (no discernible
neuropathology) to grade 4 (95% of neuronal loss in caudate nuclei).
9Characteristic insoluble protein aggregates are found in HD but also in other polyglutamine
diseases as well as other neurological disorders, such as the Lewy bodies in Parkinson’s
disease, the plaques and tangles in Alzheimer’s disease or the Bunina bodies in ALS. These
aggregates, which are ubiquitinated, are called neuronal nuclear inclusions (NIIs) or
dystrophic neuritic inclusions (DNIs), depending on their sub-cellular localization (DiFiglia et
al., 1997). Inclusions are mainly found in the striatum and cortex and partially overlap with
the neuronal pathology. Their direct impact on the disease is still under debate, as both
protective as well as toxic functions have been described (Klement et al., 1998; Saudou et al.,
1998; Sisodia, 1998; Kim et al., 1999; Rubinsztein et al., 1999; Yang et al., 2002).
1.1.5. Link between chorea and striatal degeneration
The primary motor dysfunctions in HD are due to the degeneration of a subset of striatal
neurons. The striatum belongs to a system called basal ganglia (Figure 3), which are a
collection of subcortical nuclei that are involved in the control of movement. The basal
ganglia do not receive direct sensory input and send little output to the spinal cord. The major
flow of information arrives from the cortex into the striatum and returns to the cortex through
the thalamus, which is the major output structure of the basal ganglia.
A classical model developed by Albin et. al. in 1989 described two major neuronal motor
pathways, which act in opposition, and correctly predicts the motor impairment in
Huntington’s disease. The ‘direct pathway’ promotes movements by a relay of two inhibitory
synapses, first in the globus pallidum internal segment and the substantia nigra pars reticulata
(Gpi/SNr) and second in the thalamus; the ‘indirect pathway’ inhibits movement by three
inhibitory connections in the globus pallidum external segment (Gpe), the substantia nigra
pars compacta (SNc) and the thalamus with a relay of GABAergic inhibition between the SNc
and SNr. A more recent view of the basal ganglia functions indicates that in addition from the
striatum, the subthalamic nucleus also receives input from the cortex (Mink and Thach, 1993;
Nambu et al., 2000) and sends output to the Gpi/SNr. This new cortico-subthalamo-pallidal
loop is called ‘hyperdirect pathway’ (Nambu et al., 1996) and acts by inhibiting the thalamus
and cortex. As this loop is not modified in HD, the model proposed by Albin correctly
predicts the motor defects present in Huntingon’s disease (Figure 3) as well as in Parkinson’s
disease and ballism.
According to this model, the prevalent loss of striatal GABAergic neurons projecting to the
Gpe, in the early stage of HD reduces the ‘inhibitory pathway’, thus causing an imbalance in
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favor of the direct pathway. Movements are therefore initiated, but can neither be controlled
nor stopped (Albin et al., 1989). At later stages, the general loss of the GABAergic medium
size spiny neurons (MSN), including those projecting through the ‘direct pathway’, induces a
drastic motor dysfunction leading to bradykinesia.
Figure 3: Basal ganglia, their associated structures and the motor loops
(A) Schema of a coronal section of the human brain, showing the position of the basal ganglia and their different
sub-nuclei in green. Adapted from (Bear et al., 1996)
(B) Schematic diagram of the cortico-STN-Gpi/SNr ‘hyperdirect’ pathway, cortico-striato-Gpi/SNr ‘direct’
pathway, and cortico-striato-Gpe-STN-Gpi/SNr ‘indirect’ pathway. Green filled arrows represent excitatory
glutamatergic, brown arrows represent the inhibitory GABAergic (GABA) projections and the light-brown arrow
represents the loss of GABAergic neurons projecting to the Gpe, which are impaired in the early stage of HD.
Gpe, external segment of the globus pallidus; Gpi, internal segment of the globus pallidus; SNr, substantia nigra
pars reticulata; STN, subthalamic nucleus; Str, striatum; Th, thalamus. Adapted from (Nambu et al., 2002).
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1.2. HUNTINGTIN
1.2.1. Huntingtin: searching for functions
The human huntingtin gene contains 67 exons spanning over 200 kb and is located in the
beginning of the short arm of chromosome 4 at position 4p16.3 (Figure 4). The translated
protein contains 3144 amino acids with a molecular weight of 347855 Da (reference with 23
polyQ). Despite the fact that more then 10 years have past since the discovery of htt, this
protein is still keeping its secret. Htt has very little homology to other proteins and its
functions are not yet known. There are no distinguishable features which could help predict
its biological role: no membrane spanning domains, and no apparent enzymatic activity.
HD gene
Figure 4: Position of huntingtin
Human chromosome 4 with indicated the location of the HD gene at the top of the short arm
(Entrez accession number P42858)
Htt is widely expressed within the body with the highest levels in brain and testis. In the
brain, it can be found in highest levels in the cerebellar cortex, the neocortex, the striatum and
the hippocampus (Schmitt et al., 1995). Htt is expressed predominantly in neurons (Sapp et
al., 1997) and is required for normal embryogenesis, as knockout mice die at an early
developmental stage (E 7.5) (Nasir et al., 1995). Conditional knockouts have demonstrated
that htt also has an essential role at postnatal stages, as the inactivation of the gene in brain
and testis leads to degeneration of these two tissues (Dragatsis et al., 2000). These studies
indicate that htt is required for cell survival and suggest that a loss of function of htt could
induce neurodegeneration, although with a pathology different from HD. Humans with a
partial deletion of the distal part of the chromosome 4p16.3, which includes the HD gene, are
affected by the Wolf Hirschhorn Syndrome, which is characterized by growth and mental
retardation and a premature death at 2 years, but lacks a HD-like phenotype. It is, however,
worth noting that knockout neurons in vitro differentiate and develop functional synapses
(Metzler et al., 1999).
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Interacting
protein
PolyQ-length
dependence
Region of htt
involved
Function References
α-adaptin/C/HYP-J Yes  NT (aa 1-550) Endoctosis  (CT) (Faber et al., 1998)
Akt/PKB No S421 Kinase (S) (Humbert et al., 2002)
β-tubulin No Unknown structure, vesicle transport (CT) (Hoffner et al., 2002)
CA150 No Unknown Transciptional activator (T) (Holbert et al., 2001)
Calmodulin Yes Unknown Calcium-binding regulatory protein (Bao et al., 1996)
CBP Yes NT (aa 1-588) Transciptional co-activator with
acetyltransferase activity (T)
(Steffan et al., 2000; Chai et al.,
2001)
CIP4 Yes NT (aa 1-152) cdc42-dependent signal transduction (Holbert et al., 2003)
CtBP Yes  PLDLS motif (aa
182-186)
Transcription factor (T) (Kegel et al., 2002)
Cystabthionine β -
synthase
No NT (aa 1-171) Generation of cystein (M) (Boutell et al., 1998)
FIP2/HYP-L Unknown NT (aa 1-150) Cell morphogenesis (S) (Faber et al., 1998; Hattula and
Peranen, 2000)
GAPDH Yes Polyproline Glycolitic enzyme (M) (Burke et al., 1996)
GRb2 Unknown Polyproline Growth factor receptor-binding protein
(S)
(Liu et al., 1997)
HAP40 Unknown CT Unknown (Peters et al., 2002)
HIP1 Yes  NT (aa 1-540) Endocytosis, proapoptotic (CT) (Kalchman et al., 1997; Wanker et
al., 1997; Karpuj et al., 1999)
HIP2 No NT (aa 1-540) Ubiquitin-conjugated enzyme (M) (Kalchman et al., 1996)
HIP14/HYP-H Yes  NT (aa 1-550) Trafficking, endocytosis (CT) (Singaraja et al., 2002) (Faber et
al., 1998)
HYP-A,B Yes Polyproline RNA splicing factors (T) (Faber et al., 1998)
HYP-C Yes Polyproline Transcription factor (T) (Faber et al., 1998)
IP31 Yes NT (aa 1-171) Calcium release channel (S) (Tang et al., 2003)
MLK2 Yes First three exons JNK activator (S) (Liu et al., 2000)
N-CoR Yes NT (aa 1-171) Nuclear receptor co-repressor (T) (Boutell et al., 1999)
NFκB Unknown HEAT repeats Transcription factor (T) (Takano and Gusella, 2002)
p53 No PRD Transcription factor (T) (Steffan et al., 2000)
PACSIN1 Yes PRD Endocytosis, actin cytoskeleton (CT) (Andrade and Bork, 1995)
PSD-95 Yes  PRD Synaptic scaffolding protein (CT) (Sun et al., 2001)
RasGAP Unknown PRD Ras GTPase activating protein (S) (Liu et al., 1997)
REST/NRSF Yes  Unknown repressor element 1 transcription factor
(T)
(Zuccato et al., 2003)
SC35 Spliceosome (T) (Kegel et al., 2002)
SGK S421 Kinase (S) (Rangone et al., 2004)
SH3GL3 Yes PRD Endocytosis (CT) (Sittler et al., 1998)
Sin3a Yes NT (aa 1-171) Transcription repressor (T) (Steffan et al., 2000)
SP1 Yes NT (aa 1-171),
NT (aa 1-480)
Transcription factor (T) (Dunah et al., 2002; Li et al., 2002)
TAFII-130 No NT (aa 1-480) Transcription factor (T) (Dunah et al., 2002)
TBP Unknown Unknown Basal transcription factor (T) (Huang et al., 1998)
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Table 1: Proteins interacting with huntingtin
The proteins found so far to interact with huntingtin are listed in alphabetical order. The table shows if these
interactions are increased () or decreased () by the polyglutamine expansion, the domain where htt interact and
the principal function of these proteins. (CT: cellular trafficking, M: metabolism, PRD: proline reach domain, S:
signaling and T: transcription. The table was adapted and completed from (Petérsen et al., 1999; Cattaneo et al.,
2001; Harjes and Wanker, 2003; Li and Li, 2004).
Htt functions are not well known, but the list of proteins interacting with huntingtin is
growing. To date, 35 proteins have been described in the literature (Table 1). By regrouping
these proteins, four functional families can be formed: the ‘transcription’ family (T) with 15
proteins is the largest, the ‘cellular trafficking’ family (CT) has 9 members, the ‘signaling’
family (S) has 8 proteins and the ‘metabolic’ family (M) has 3 members. The high number of
transcription factors interacting with htt suggests an important role of htt in gene control.
Except for REST, all the interacting factors are nuclear and hence required the presence of htt
in the nucleus. It is therefore probable that these interactions are relevant in HD pathology as
the mutation induces a nuclear translocation of htt. The second largest family of proteins
interacting with huntingtin are involved in cellular trafficking. This is in agreement with htt
colocalization in the endoplasmic reticulum, microtubules, mitochondria, clathrin-coated
vesicles and synaptosomal fraction (DiFiglia et al., 1995; Sharp et al., 1995; Gutekunst et al.,
1998; Velier et al., 1998). Indeed, wild type huntingtin is essentially a cytoplasmic protein
(DiFiglia et al., 1995; Trottier et al., 1995), however it is also found in minor quantities in the
nucleus (Wheeler et al., 2000; Tao and Tartakoff, 2001; Kegel et al., 2002).
The protein contains 36 HEAT-like repeats (Huntingtin, Elongetion factor 3, regulatory A
subunits of protein phosphatase 2A and TORI), which are distributed across the entire protein
(Takano and Gusella, 2002). HEAT motifs are sequences of about 40 amino acids, which
form hydrophobic α helices and assemble into an elongated superhelix (Andrade et al., 2001)
(Figure 5). The function of HEAT repeats is still unclear, although they are found
predominantly in proteins involved in intracellular trafficking and chromosomal segregation.
This suggests that huntingtin may act as a scaffold molecule facilitating the formation of
variety of complexes, analogous to other HEAT repeat proteins (Takano and Gusella, 2002).
Figure 5: Structure of HEAT repeats
Tertiary structure of HEAT repeats of the protein
phosphatase 2A PR65/A from H. sapiens, which is
an open solenoid-like structure. The structure of
huntigntin is probably analogous to this protein.
Individual motifs are composed of a pair of α-
helices that assembles in a mainly linear, repetitive
fashion to form an elongated molecule
characterized by a double layer of α-helices. Left-
handed rotations generate a novel left-hand
superhelical conformation. The protein interaction
interface is formed from the intrarepeats that are
aligned to form a continuous hydrophobic ridge
(Groves et al., 1999).
One of these functional complexes is composed of HAP1, dynactin p150 and is involved in
microtubule-dependent transport of vesicles and interacts with beta-tubulin (Engelender et al.,
1997; Li et al., 1998; Gauthier et al., 2004). A second complex is formed with HIP1, actin and
clathrin and participates in vesicle endocytosis (Waelter et al., 2001). A IP31-HAP1A-htt
ternary complex might be involved in calcium signaling in the endoplasmic reticulum (Tang
et al., 2003). PACSIN 1 and SH3GL3, the binding partners for dynamin 1, are both involved
in synaptic vesicle recycling and both interact with htt (Sittler et al., 1998). In addition, htt
associates with postsynaptic density 95 (PSD-95), a scaffold protein that causes clustering and
activation of receptors in the postsynaptic membrane (Sun et al., 2001). Htt could also be
implicated in gene regulation by acting in the cytoplasm to inhibit gene transcription by
associating with the repressor element-1 transcriptional factor (REST), which would prevent
its nuclear translocation. In the nucleus, REST inhibits gene transcription by binding to the
NRSE-consensus sequence, which is found in the promotors of several neuronal genes.
Interestingly, the expression of one of these regulated genes is the neurotrophic factor BDNF
(Zuccato et al., 2003), which is decreased in HD brains which and has been described as
playing an important role in the survival of striatal neurons (see 1.2.3).
1.2.2. Mutant huntingtin: when length does matter
Downstream amino acid 17 of htt is a polymorphic glutamine/proline (Q/P) rich domain. The
expansion of a glutamine stretch encoded by the nucleic acids (CAG)n will cause
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Huntington’s disease. There is a strong inverse correlation between the number of CAG
repeats found in the htt gene and the age of disease onset (Figure 6). However, other genetic
and environmental factors influence the age of appearance of the first HD symptoms
(Rubinsztein et al., 1997; Holbert et al., 2001; Wexler et al., 2004). To date, 11 disorders with
CAG expansion in the coding region of proteins have been found. Interestingly all are
neurodegenerative diseases, almost all are characterized by the presence of insoluble
ubiquitinated aggregates and a degeneration of specific brain regions, despite the ubiquitous
expression of the corresponding proteins. These other members of the triplet repeat disease
family are: spinobulbar muscular atrophy (SBMA), spinocerebellar ataxias
(SCA1,2,3,6,7,8,12 and 17) and the dentatorubralpallidoluysian atrophy (DRPLA).
Figure 6: Frequency of CAG repeat size on normal and HD chromosomes
(A) Box plot of age of onset and repeat length of the longer allele. The curvilinear relationship between the two
variables can be observed. It also is important to note the large variability of age of onset values, even within
each repeat length. (B) Histogram of the longer allele repeat length in the Venezuelan HD kindred. Repeat length
ranges are defined as normal (14–34 CAGs), incompletely penetrant (35–39 CAGs), and fully penetrant (40
CAGs) (Wexler et al., 2004).
In HD, CAG repeat numbers between 8-28 are associated with the normal allele, 29-35 are
pre-mutations, 36-40 have incomplete penetrance and the pathological threshold of the
disease is defined at 40 CAGs. More then 60 repeats are associated with a juvenile onset
(before 20 years). The frequency of the repeat sizes on normal and HD chromosomes is
illustrated in Figure 6B. There is no correlation between CAG repeat length and survival after
onset. Homozygous mutations do not lower the age at onset of symptoms, but it more severely
affects the phenotype and the rate of disease progression (Squitieri et al., 2003). The CAG
repeats may also undergo a somatic expansion with a frequency related to the length of the
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repeat. Indeed different expansion lengths have been found in cells from the same transgenic
mouse (Ishiguro et al., 2001). During meiosis, the risk of expansion is more frequent in
spermatogenesis as compared to oogenesis, which leads to the so-called paternal anticipation.
It is, therefore, possible that a ‘pre-mutation’, which is not associated with the disorder, will
be amplified and will reach the pathological threshold in the offspring (Trottier et al., 1994).
1.2.3. Possible toxic mechanisms of mutant huntingtin
HD is an autosomal dominant disorder. This suggests that the mutation leads to a toxic gain of
function. Accordingly, several cellular and animal models were developed by over-expressing
mutant huntingtin. But there is evidence that a loss of protective function of huntingtin could
act synergistically with the gain of toxic functions. The more puzzling aspect of HD is to
understand why mutant htt, which is not particularly highly expressed in the striatum as
compared to other brain regions, leads to a specific neuronal degeneration. In this chapter I
will discuss several non-exclusive hypotheses that have been proposed to describe the toxic
mechanisms induced by mutant htt.
a)  The toxic fragment hypothesis
The toxic fragment hypothesis is based on the observation that mutant huntingtin is cleaved
both in cellular models, in transgenic animals and in HD patients (Sieradzan et al., 1999). The
cleavage produces N-terminal fragments bearing the polyglutamine (polyQ) expansions which
are considered to be the toxic compounds. Several experiments have shown that the
expression of different N-terminal fragments with expanded polyQ is sufficient to induce a
HD-like pathology, whereas longer fragments are less toxic in cellular and animal models
(Lunkes and Mandel, 1998; Saudou et al., 1998; Karpuj et al., 1999; de Almeida et al., 2002).
Short fragments may induce toxicity in the cytoplasm by promoting aberrant interactions with
proteins and by inducing formation of aggregates. In addition, once cleaved, htt fragments can
translocate from the cytoplasm into the nucleus, where they aberrantly interact with several
transcription factors and form inclusions (Ross, 2002). This is supported by the fact that
cleavage of mutant htt promotes aggregate formation (Cooper et al., 1998; Li and Li, 1998;
Martindale et al., 1998). The toxic fragment hypothesis is however non-exclusive and does
not contradict other postulated mechanisms, such as the aggregation or the transcriptional
dysregulation hypothesis.
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Figure 7: huntingtin consensus cleavage sites
The schema shows the huntingtin protease domains and the position of the known cleavage sites of caspases,
calpains and aspartyl proteases. Adapted from (Wellington et al., 2003).
Several consensus cleavage sites have been identified in htt (Figure 7). Experiments have
shown that preventing proteolysis by inhibition of caspase or calpaine activation or by
modifying the consensus cleavage site in htt reduces mutant huntingtin toxicity in vitro and in
vivo HD models (Ona et al., 1999; Sanchez et al., 1999; Wellington et al., 2000; Gafni and
Ellerby, 2002). Based on this hypothesis, the inhibition of huntingtin proteolysis could be an
effective therapy against HD. Interestingly, the phosphorylation of huntingtin prevents mutant
htt cleavage, aggregation and finally toxicity (Saudou et al., 1998; Humbert et al., 2002;
Rangone et al., 2004). Therefore factors such as IGF-1, which induces the phosphorylation of
htt, could be effective against HD.
b)  The aggregation and protein turnover hypothesis
Using electron microscopy and X-ray diffraction Perutz and collaborators demonstrated that
polyQ forms cylindrical β-sheets strongly interacting via hydrogen bonds, which could act as
‘polar zippers’ leading to protein aggregation and precipitation (Perutz, 1994; Perutz et al.,
1994; Perutz et al., 2002). The threshold for huntingtin aggregation in vitro appears to be 35-
48 glutamine residues, which closely approximates the critical range for the development of
HD (Scherzinger et al., 1997). Progressive accumulation of abnormal protein aggregates
associated with neuronal loss is a common molecular event observed in all polyQ diseases,
but also in other neurodegenerative diseases such as PD, AD or ALS. A slow increase in
protein accumulation could occur if the protein turnover is affected or the processing of the
mutant form is less efficient. Huntingtin turnover could be tightly regulated by cleavage, and
the proteolysis might be involved in the pathology in several ways. For example, the toxic
fragment might be resistant to further degradation. The fact that the ubiquitin-proteasome
pathway (UPP) is impaired by polyQ expansions strongly suggests that the protein turnover is
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indeed affected in polyglutamine diseases (Bence et al., 2001). A generalized proteasomal
inhibition was recently described to occur, not only in brain regions affected by HD, but in
other CNS territories and also in fibroblasts from HD patients (Seo et al., 2004). UPP
impairments are also associated with other neurodegenerative diseases. A mutation in a
protein of the ubiquitin pathway, the ubiquitin carboxyl terminal hydrolase L1 (UCHL-1) and
mutations in parkin, which is a ubiquitin ligase (E3), cause familial forms of Parkinson’s
disease (von Bohlen und Halbach et al., 2004). Several studies in cellular and animal models,
and also data from human brains, have shown that large aggregates colocalized with ubiquitin
and chaperones, suggesting that the mutant protein is recognized as misfolded and is targeted
for protein degradation. Overexpression of the chaperone HSP70 in a fly model of SCA3
suppresses polyQ-induced pathology without reducing aggregation, but by decreasing the
soluble mutant protein content (Warrick et al., 1999; Pollitt et al., 2003). This suggests that
aggregation has a protective function by sequestrating the toxic compound. The suppression
of aggregates by the expression of a dominant negative ubiquitin-conjugating enzyme in a
cellular model of HD increased mutant htt toxicity (Saudou et al., 1998). On the other hand,
aggregates could sequester important transcription factors, leading to transcriptional
abnormalities, as discussed below. Finally, they could block axonal and dendritic trafficking,
leading to neuronal dysfunction (Gunawardena et al., 2003; Lee et al., 2004).
A current view of α-sinuclein toxicity imputes small aggregates, rather than mature fibrils, to
be the pathogenic factor (Lashuel et al., 2002). Similarly, mutant htt oligomers, but not htt
aggregates, may inactivate transcriptional factors. In support of this view, a recent study with
purified proteins expressed in Echerichia coli showed that soluble mutant htt interacts with
TBP and CBP prior to aggregation, and htt aggregates lose the ability to bind these
transcription factors (Schaffar et al., 2004), thus adding new evidence that monomers and/or
oligomers, but not aggregates are the toxic compounds. All this data seams to show that at a
first step, aggregate formation is protective as it inactivates the toxic species, but at a later
stage, the accumulation of large aggregates leads to a physical impairment.
Several compounds reducing aggregation have been tested in vitro and in vivo, such as the
dye congo red or more recently sugar trehalose, which decreased aggregation and neuronal
pathology in the transgenic mouse model R6/2 (Smith et al., 2001; Sanchez et al., 2003;
Tanaka et al., 2004).
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c) Transcriptional dysregulation
The hypothesis that mutant htt, but also other polyQ proteins affect nuclear functions,
emerged when it was noted that nuclear translocalization increases toxicity in cell culture
models and transgenic mice (Klement et al., 1998; Saudou et al., 1998; Peters et al., 1999). In
addition, the disease progression in humans and animal models is correlated with the
accumulation of nuclear aggregates that may sequester transcription factors and other cellular
proteins (Boutell et al., 1999; Steffan et al., 2000; Zoghbi and Orr, 2000; Nucifora et al.,
2001; Ross, 2002).
The majority of transcription factors (T) interacting with htt associate with the domain rich in
glutamine residues and the interaction is polyQ-length-dependent (Table 1). Moreover, the
ectopic presence of mutant htt fragment in the nucleus strongly modifies the physiology of htt
activity. The expanded htt protein interacts with the acetyl transferase domain of different
transcription factors such as CBP (cAMP-response element binding protein (CREB) binding
protein) and p300/CBP Associated Factor (P/CAF), which affects histone deacetylase,
chromatin structure and finally gene transcription (Steffan et al., 2001). Other transcription
factors which interact with htt are the TATA box binding protein (TBP) and Sin3A (Dunah et
al., 2002). Recently, it was shown that monomers and small soluble oligomers of mutant htt
exon 1 inactivate transcription factors, including CBP and TBP, by a polyQ-mediated
interaction (Schaffar et al., 2004). Dysregulations of gene transcription are, therefore,
considered to play an important role in HD. Indeed, DNA-microarray experiments on
transgenic mice and cell cultures have reveled several transcriptional changes, most often a
relative reduction of transcripts, induced by the polyQ expansions (Luthi-Carter et al., 2000;
Nucifora et al., 2001; Wyttenbach et al., 2001; Sipione et al., 2002). Besides the
downregulation of important mediator of cell survival via CRAB, transcriptional dysfunctions
may also induce the overexpress of proapoptotic genes via activation of the JNK/c-Jun
module (Garcia et al., 2002). To restore normal transcriptional activity, the over-expression of
transcription factors such as CBP and CA150 has been considered to be neuroprotective
against mutant htt toxicity (Steffan et al., 2000; Holbert et al., 2001; Nucifora et al., 2001). In
addition, chemical compounds that such as inhibit histone deacetylase, such as sodium
butyrate and suberoylanilide hydroxamic acid, reduced polyglutamine toxicity in cell lines,
transgenic flies and mouse models of HD (McCampbell et al., 2001; Steffan et al., 2001;
Ferrante et al., 2003; Hockly et al., 2003).
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d) The loss of function hypothesis
The hypothesis that a loss of function could play a role in HD pathology was first reported
when it was shown that wild type huntingtin has anti-apoptotic function (Rigamonti et al.,
2000; Rigamonti et al., 2001). In addition, its over-expression rescues mutant-htt-induced
toxicity in cellular models, suggesting that the mutation could interfere with an endogenous
pro cell-survival function of htt (Cattaneo et al., 2001; Sipione and Cattaneo, 2001;
Rubinsztein, 2002). This protection could occur through the interaction with REST (see
1.2.1), which is decreased by the polyglutamine expansion. Interestingly, REST controls
cortical BDNF expression. BDNF is anterogradely transported to the striatum and is
decreased in HD, transgenic mice and cellular models (Ferrer et al., 2000; Zuccato et al.,
2001; Zuccato et al., 2003). This chronic depletion could contribute to HD pathology and
partially explain the preferential striatal vulnerability. Conditional knockout mice of forebrain
BDNF confirmed the importance of this trophic factor for striatal dendrite morphology and
for a long-term survival of MSNs (Baquet et al., 2004). In addition, these knockout mice show
noticeable analogies to transgenic HD mice, with a reduction of striatum volume, a late
neuronal loss and a clasping phenotype. These data suggest that restoring striatal BDNF may
represent a therapeutic approach for HD.
The anti-apoptotic effect of wild-type htt may also occur via the sequestration of pro-
apoptotic molecules such as Hip1, which once dissociated from huntingtin forms a complex
with Hippi and activates caspase 8 (Gervais et al., 2002). In accordance with the loss of
function hypothesis, wild type htt has been proposed as therapeutic factor (Leavitt et al., 2001;
Cattaneo, 2003).
e) Mitochondrial impairment
Energy metabolism impairments have been described in affected brain regions of HD,
including an increase in lactate levels, a decrease in N-acetylaspartate and creatine and a
reduction of complex-II and complex-III activities. In addition, HD patients progressively
loose weight despite high caloric intake. All these findings strongly suggest a mitochondrial
dysfunction in Huntington’s disease (for review see (Beal, 2000)). Mitochondrial impairment
could contribute to excitotoxic processes, oxidative damage, and altered gene regulation.
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Striatal neurons are highly innervated by cortical excitatory input and require important
energy supplies to maintain a physiological depolarized state. Energy failure would over-
activate striatal NMDA receptors inducing so-called ‘secondary excitotoxicity’. Striatal
vulnerability to mitochondrial impairment was accidentally discovered after the intoxication
of Chinese children with 3-nitropropionic acid (Ming, 1995). This toxin irreversibly inhibits
succinate dehydrogenase (mitochondrial complex-II) and leads to a severe neurological
disease resembling HD, with a degeneration of basal ganglia and movement dysfunctions
characterized by distonia, chorea and hypokinesia (Ludolph et al., 1991; Alexi et al., 1998). A
generalized mitochondrial impairment seems to occur in HD; lymphoblast mitochondria of
HD patients and transgenic mice have a lower membrane potential (Panov et al., 2002; Panov
et al., 2003). It was shown that htt associates with the mitochondrial outer membrane and that
mutant htt N-terminus decreases the calcium threshold required to induce mitochondrial
permeability transition (MPT) pore opening and release of cytochrome c (Choo et al., 2004),
which can activate apoptotic death pathways. Interestingly, neurons with high calcium buffer
(e.g. calbindin positive) are spared in the striatum (Ferrer et al., 1994). Potential
neuroprotective strategies are the administration of creatine, which may exert neuroprotective
effects by increasing phosphocreatine levels or by stabilizing the mitochondrial permeability
transition, the administration of co-enzyme Q10, a carrier for electron-transfer in the
mitochondrial membrane or remacemide an NMDA antagonist. These compounds are
neuroprotective in transgenic mouse model R6/2 and are currently being tested in clinical
trials (Ferrante et al., 2000; Ferrante et al., 2002).
e)  Excitotoxicity hypothesis
Excitotoxicity could play an important role in HD, as cortical glutamatergic processes
massively innervate the striatum. The overactivation of N-methyl-D-aspartate (NMDA)-type
glutamate receptors allows high levels of calcium entry can results in the death of MSN
neurons (Ferrante et al., 1985; Lipton and Rosenberg, 1994). Calcium triggers different
downstream events, such as activation of calpain, protein kinase C, DNAase, phospholipase
and can induce cell death either by necrosis or apoptosis (Lynch and Guttmann, 2002).
Notably, significant increases in the NMDAR-mediated current density associated with an
increase of intracellular free calcium levels were found in MSNs from several mouse models
for HD (Levine et al., 1999; Cepeda et al., 2001; Zeron et al., 2002; Zeron et al., 2004). At a
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molecular level, huntingtin interacts with PSD-95, a post-synaptic protein that can modulate
excitory signaling through the interaction with NMDA receptors (Aarts et al., 2002). Mutant
htt promotes sensitization of NMDA and the over-expression of the wild type reduce NMDA
or kainate-mediated toxicity in a neuronal cell line (Gratacos et al., 2001a; Sun et al., 2001).
1.2.4. Dysfunction and death of striatal neurons
As discussed in the previous chapter, several mechanisms of mutant huntingtin toxicity have
been proposed, which partially fit with clinical data gathered from HD patient as well as from
molecular, cellular and animal experiments. These different mechanisms could participate
synergistically in the pathology or be subordinate to one of them. The fact that there are
generalized biochemical abnormalities in cells from HD patients, but only a specific cell death
(Seo et al., 2004), suggests that several accomplices are needed to finally induce striatal
neuronal death.
Whether the cell death in the striatum is cell-autonomous or involves other brain regions is
still an open question. Dysregulation of cortical glutamatergic input could lead to
excitotoxicity, and the decrease of cortical BDNF delivery either by transcriptional
dysregulation or by impairment in vesicle transport could lead to a trophic starvation of
striatal neurons. In addition, the massive release of dopamine in the striatum could activate
oxidative stress pathways and autophagy (Petérsen et al., 2001a). On the other hand, cell
autonomous dysfunctions have been observed, such as mitochondrial impairment,
aggregation, gene transcriptional changes and htt cleavage, which would speak more for a
cell-autonomous death. Again, the combination of these two factors could lead together to this
specific cell death.
During the last 30 years, cell death was usually classified either as apoptosis or as necrosis
(Kerr et al., 1972). Classical necrosis is unlikely to be responsible for the cell loss in HD,
because it involves cell swelling and rupture, electing an inflammatory response, a violent and
quick form of degeneration affecting extensive cell populations. Programmed cell death is
therefore more likely to be involved in HD neuronal death. Caspase activation is one of the
indicators of apoptotic mediated cell death and as previously discussed is involved in the
cleavage of htt and is activated in HD (Ona et al., 1999; Sanchez et al., 1999). In addition,
fragmented chromatin was described in HD striatal tissues. Despite this, evidence of apoptotic
neuronal death in HD is scarce. The simplest dichotomy, necrosis or apoptosis, was shown to
23
be insufficient and autophagy was added as an alternative type of cell death. Autophagy is a
primary mechanism of cell physiology that digests long-lived stable proteins and organelles,
but it is also a potential mechanism of cell death. Mutant huntingtin can be taken up and
degraded by autophagic vacuoles (Michalik and Van Broeckhoven, 2003; Qin et al., 2003).
Accumulation of proteasamal-resistant htt aggregates could therefore lead to a chronic
activation of this pathway, which could induce cell death by autophagy. Indeed, a number of
studies have demonstrated the presence of autophagy in HD brain and in animal models of
HD (Larsen and Sulzer, 2002). Cellular models of HD have highlighted the presence of
autophagic bodies (Kegel et al., 2000; Petérsen et al., 2001a). In conclusion, several features
of apoptotic and autophagic cell death are present in HD, it is possible that a cross-talk of this
two alternative cell death pathway are involved in the mutant htt mediated cell death.
1.3. MODELING HD: FROM CHEMICAL TO GENETIC INSULTS
Before the emergence of genetic models, different toxins were delivered to rodents and
primates to reproduce a HD-like phenotype (Brouillet et al., 1999). The over-stimulation of
glutamate receptors with excitatory amino acids such as ibotenic acid, kainic acid, N-methyl-
D-aspartate (NMDA) or quinolinic acid, induces neuronal death by excitotoxicity (Bruyn and
Stoof, 1990). The activation of this pathway, as discussed in chapter 1.2.3, could be relevant
to HD pathology.
The second strategy to induce striatal degeneration consists in the systemic administration of
mitochondrial blocker 3-nitroproprionic acid, which inhibits succinate dehydrogenase, leads
to ATP depletion, and reproduces a specific striatal degeneration of GABAergic neurons. This
model is based on the hypothesis that chronic impairment of the mitochondrial metabolism
may induce neuronal death (sees chapter 1.2.3).
These chemically induced models were, and still are, useful tools to test therapeutic strategies
which can spare striatal neurons and could therefore be interesting for HD. On the other hand,
these models do not reproduce the progressive chronic neuronal degeneration and lack the
genetic component of HD. Therefore their interest has decreased in favor of huntingtin-based
models.
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1.3.1. Molecular models
Almost 40 years ago, the aggregation properties of polyglutamine stretches in a test tube were
discovered (Krull et al., 1965) and, without being aware of it, the first polyQ model was
concomitantly developed. These cell-free systems are suitable to investigate the biochemical
parameters leading to conformational change, protein sequestration and aggregation, as well
as to being screen for chemical compounds which could interfere with this processes. (Perutz,
1994; Perutz et al., 1994; Scherzinger et al., 1997; Perutz et al., 2002; Schaffar et al., 2004).
1.3.2. In vitro models
These models are obtained either from knock-in mice or by the expression of mutant
huntingtin, a huntingtin fragment or a polyQ expansion in different cell types, including yeast,
cell lines, or primary cultures. Yeast, Saccharomyces cerevisiae, provide a useful tool for the
screening of genes involved in aggregate formation, to study potential polyQ-induced toxicity
and for the screening of chemical compounds (Lindquist et al., 2001; Muchowski et al.,
2002). For example, the importance of chaperone-mediated folding of polyglutamine
expansions was discovered in yeast. The molecular chaperone Hsp104 was reported to be
essential for the aggregation of polyQ peptides containing proteins, and over-expression of
Hsp70 and Hdj1 (yeast homologue of Hsp40) suppressed the formation of fibrous deposits,
but promoted amorphous, detergent-soluble aggregates (Krobitsch and Lindquist, 2000;
Muchowski et al., 2000).
Several mammalian cell lines that are stably over-expressing mutant or wildtype huntingtin
were developed (Lunkes and Mandel, 1998; Jana et al., 2000; Rigamonti et al., 2000;
Wyttenbach et al., 2001). Neuronal cell lines or primary neuronal cultures obtained from htt
knock-in mice (see 1.3.3) are particularly interesting because of the physiological expression
of mutant htt, but the absence of a severe phenotype is a major limitation to study HD
pathology (Trettel et al., 2000). Other models obtained by culturing dissected striata from
transgenic mice were characterized by mild pathology and no cell death under stable culture
condition (Petérsen et al., 2001b; Zeron et al., 2004). Saudou et al. (1998) were the first to
develop a model in primary striatal neurons transfected with mutant huntingtin, and to
reproduce the typical features such as protein aggregation and neuronal death. However the
low transfection rate is a major limitation of that model. In summary, all these different
models show that mutant huntingtin is toxic when over-expressed in different cell types, but
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endogenous or low expression induces only subtle changes. A balance between survival of the
culture in vitro and the level of htt expression should be found to obtain a progressive, but
severe pathology.
1.3.3. In vivo genetic animal models
A breakthrough in HD research was the development of transgenic models. These animals are
valuable tools for determining the first molecular changes associated with the disease,
highlighting which toxic pathways are activated and finally testing effective therapies.
With only 302 neurons, the nematode Caenorhabditis elegans is the simplest genetic animal
model of HD (Faber et al., 1999; Holbert et al., 2001; Parker et al., 2001; Faber et al., 2002).
Biochemical and morphological studies, as well as behavioral tests can be performed in this
classical genetic animal model. In addition, its transparency allows longitudinal live imaging
studies in vivo with standard microscopy equipment.
The fruit fly, Drosophila melanogaster, is a second invertebrate model for HD, where
degeneration of photoreceptors and motor function are often measured (Jackson et al., 1998;
Steffan et al., 2001; Gunawardena et al., 2003). PolyQ-expressing flies form nuclear
inclusions and undergo a progressive neurodegeneration, leading to early cell death. The ease
in developing different transgenic flies or worms makes them an ideal platform to screen for
genetic or chemical modifiers, which would interfere with the polyQ-induced pathology in
vivo.
Mammals and especially the mouse, mus musculus, are the favorite animals chosen to model a
human pathology. Transgenic mice expressing the first exon of htt with 115 CAG (strain line
R6/1) or 155 CAG (strain line R6/2) repeats, develop progressive behavioral symptoms and
neuropathology, but little evidence for cell loss could be found (Mangiarini et al., 1996;
Murphy et al., 2000; Turmaine et al., 2000; van Dellen et al., 2000). Various other mouse
lines have been developed thereafter, each characterized by different promoter, expression
levels, htt length and polyQ expansion (see Table 2). Knock-in mice with the murine htt
bearing polyQ expansion are close models of the HD genetic state, as they express mutant
huntingtin at endogenous levels. Similarities between all these mouse strains have been
reported with respect to inclusion formation, brain atrophy, tremors, hyperactivity and
clasping phenotype. A few studies reported cell loss but only at an old age, for example in the
YAC72 and YAC128, which express the full-length htt with 72 and 128 glutamines,
respectively.
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In addition, a transgenic rat model of Huntington’s disease was developed, showing
phenotype similar to transgenic mice, and allowing extensive longitudinal study in vivo with
high resolution imaging (von Horsten et al., 2003), but again this model displayed little
neuronal loss.
Finally, a new strategy for generating genetic animal models has been developed by the
striatal injection of viral vectors encoding portions of the mutated protein. The first model was
obtained by the delivery of a polyQ-GFP fusion protein mediated with an AAV viral vector
(Senut et al., 2000). Moreover, lentiviral-mediated striatal expression of mutant htt fragments
in rats and primates represents a good tool to analyze the impact of the mutation in a specific
brain region. These models have finally shown, for the first time, a severe neuronal
degeneration followed by cell death (de Almeida et al., 2002; Régulier et al., 2003).
Transgenic mice may therefore be more suitable to analyze early pathological dysfunctions
and lentiviral- based models may be more appropriate to study neuroprotective strategies.
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Group
Promoter
gene size
polyQ
expression
Onset
behavior Inclusions
Cell loss and
brain atrophy References
Transgenic HD mice
Bates (R6/1-2)
HD
exon1
115Q-155Q
< endogenous
5 weeks
Clasping, tremors, abnormal gait,
learning deficit, hypokinesis,
diabetes
NII and DNI
Fewer dendritic spines, few
cells lost, overall brain atrophy
(Mangiarini et al.,
1996; Turmaine et
al., 2000)
HD
full-length
72Q
2x endogenous
3 months
Clasping, hyperactivity and
circling
Inclusions in the striatum Cell loss in the striatum
(Hodgson et al.,
1999)
Hayden (YAC)
HD
full-length
128Q
6x endogenous
Motor abnormalities,
hyperactivity, end stage
hypoactivity
Inclusions
Striatal neuronal loss
Striatal and cortical atrophy
(Slow et al., 2003)
Ross/ Borchelt
PrP
N171
18,44, 82Q
5x endogenous
4 months
Clasping, tremors, abnormal gait,
hypokokinesis, weight loss, early
death
Inclusions, diffuse nuclear
accumulation of htt
dark cells
Overall brain atrophy
(Schilling et al.,
1999)
CMV
full-length
6, 48, 89Q
1-2x endogenous
4 months
Circling, hyperactivity, end stage
hypoactivity, urinary incontinence
Few inclusions
20% cell loss in striatum in
some animals
(Reddy et al.,
1998; Reddy et al.,
1999)
Tagle
CMV
exons 1-3
89Q
1/5x endogenous
4 months
Prolonged hyperactivity
Few inclusions not described Unpublished?
Aronin/DiFiglia
rat NSE
3 kb fragment
18,48,100Q
> endogenous
3-4 months
Clasping, hyperactivity and
endstage hypoactivity
Inclusions
20% cell loss and brain atrophy
in some animals
(DiFiglia et al.,
1997)
Hen/Yamamoto
tet-off(camKIIα-tTA)
HD
exon1 97Q
< endogenous
2.5 months
Clasping, late onset tremor and
gait abnormality
Inclusions and reactive
astrocytes
Brain and progressive striatal
atrophy
(Yamamoto et al.,
2000)
Knock-in HD mice
Hdh
50,92,111Q
endogenous
No abnormal behavior htt nuclear relocalization and
inclusions
not described (White et al., 1997)
MacDonald
neo and HDh
29, 111Q
< 1/2 endogenous
2 months
tremor, abnorm gait
htt nuclear relocalization and
inclusions
Brain atrophy
(Wheeler et al.,
1999; Wheeler et
al., 2000)
Myers
Hdh prom,
71,82Q
2x endogenous
early onset aggressive behaviour
Late inclusions, LTP impaired,
repeat instability in striatum not described
(Shelbourne et al.,
1999)
Zeitlin
Hdh
71, 94Q, 150Q
~ 2 endogenous
no phenotype NMDA sensitivity No inclusions
smaller striatal cell
(Levine et al.,
1999)
Transgenic HD rat
Riess
rat HD
1962 bp rat htt
51Q
Tet/off
2 months
reduction in anxiety, decline in
spatial learning test, motor
dysfunctions
htt inclusions
Focal lesion in striatum,
ventricle enlargement
(von Horsten et al.,
2003)
Lentiviral mediated HD rat
CMV, PGK
171, 853, 1520AA
19,44,66,82Q
not determined
No behaviour htt inclusions
Striatal atrophy and severe
neuronal loss
(de Almeida et al.,
2002)
Déglon/
Aebischer tTA1-PGK
853 AA
19, 82Q
not determined
No behaviour htt inclusions
Striatal atrophy and severe
neuronal loss
(Régulier et al.,
2003)
Table 2: Genetic rodent models of Huntington’s disease
The table recapitulates the major characteristics of the available transgenic and knock-in mice as well as the
transgenic and lentiviral-mediated models of Huntington’s disease. (Adapted and completed from
http://www.hdfundation.org/PDF/hdmicetable.pdf)
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1.4. THE HUNT FOR A CURE
Several hypotheses describe the mechanism of how huntingtin may act to induce neuronal
death (see 1.2.3 Possible toxic mechanisms of mutant huntingtin). Thus, several different
‘deterministic’ approaches, which could directly interfere with mutant huntingtin toxicity
have been proposed (Peschanski et al., 2004). They are summarized below:
a) Blockade of htt proteolysis with caspases and/or calpain inhibitor
b) Reduction of aggregates and/or mutant htt toxicity with chaperones and chemical
compounds
c) Up-regulation of transcription with histone deacetylase inhibitors
d) Restoring the loss of with wild-type htt functions
e) Improving the energetic state with metabolic enhancers
f) Blocking excitotoxicity with NMDA antagonist
g) Blocking the expression of mutant htt by RNA interference
On the other hand, restorative or ‘pragmatic' strategies are also proposed, which in contrary to
the deterministic approaches try to interfere directly with some effect of the disease, typically
with the striatal neuronal loss (Peschanski et al., 2004). For example, neuroprotective
strategies such as the delivery of neurotrophic factors could represent a valid option; as such
proteins have shown a strong protection of neurons in various animal models of striatal
injuries. Alternatively, the reconstruction of neuronal circuits in the brains by intrastriatal
transplantation of striatal neuroblasts from human fetuses could represent a valid option for
HD (Peschanski et al., 2004).
1.4.1. Neurotrophic factors
Neurotrophic factors are proteins which promote the survival of specific neuronal
populations. They act by inducing physiological effects such as morphological differentiation,
enhancing nerve regeneration, neurotransmitter expression, gene expression and altering the
physiological characteristics of neurons. It has been proposed that neurotrophic factors could
slow down or arrest the course of neurodegenerative diseases, or even promote regeneration.
Neurotrophins, glial cell line-derived neurotrophic factor family members and ciliary
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neurotrophic factor have shown potent neuroprotective effects on different neuronal
populations of the striatum. Thus, these neurotrophic factors may be suitable for the
development of a neuroprotective therapy for neurodegenerative disorders such as
Huntington’s disease (Alberch et al., 2004). In particular, two neurotrophic factors have
caught our interest. One is the ciliary neurotrophic factor (CNTF), which in several different
animal models has proven a high rescue potential and has been tested in a clinical trials
(Bloch et al., 2004); the other is the brain-derived neurotrophic factor (BDNF), which is a
potent neurotrophic factor for GABAergic neurons and is decreased in HD brains.
1.4.2. CNTF
Ciliary neurotrophic factor purified from chick eye was originally described to rescue neurons
from embryonic chick ciliary ganglia in vitro (Barbin et al., 1984). CNTF is not critical for the
development and for the postnatal and adult maintenance of neurons, since knockout mice
develop normally, with only subtle changes in motor survival (Masu et al., 1993). In fact
2,5% of the Japanese population have a homozygous null mutation of this factor without any
associated neurological abnormalities (Takahashi et al., 1994). On the other hand, the
knockouts of the genes coding for the CNTF receptors (CNTFRα, gp130 or LIFRβ) led to
prenatal death of mice or severe motor neuron deficits (DeChiara et al., 1995). Later, a new
heterodimeric ligand for CNTF receptor alpha (CNTFRα) the stable secreted complex of
cardiotrophin-like cytokine (CLC) and the soluble receptor cytokine-like factor-1 (CLF) was
discovered, thus resolving the apparent paradox between the results of knocking out the
neurotrophic factor or its receptor (Elson et al., 2000).
CNTF is a member of an α-helical cytokine superfamily that includes interleukin-6 (IL-6),
leukemia inhibitory factor (LIF) and leptin. CNTF lacks a signal peptide and is found in
adults in glia cells within the CNS and PNS. Its expression is highly regulated following
neuronal traumas or ischemia and is restricted to astrocytes adjacent to the lesion (Ip et al.,
1993; Asada et al., 1995). CNTF is considered an ‘injury factor’ and numerous studies have
shown neuroprotection in different models of neurodegenerative diseases (Alberch et al.,
2004).
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Figure 8: CNTF and its receptors: mode of action
The schema shows how CNTF acts in the cell. The binding of CNTF with the receptor CNTFRα induces
the formation of the heterodimeric complex with gp130 and LIFRβ . This allowing tyrosine
phosphorylation of JAKs, activation of STAT (STAT-3) and translocation of STAT homodimers to the
nucleus, where they bind to specific DNA sequences promoting gene transcription.
CNTF acts through a heteromeric receptor complex formed by the subunits CNTFRα, gp130
and LIFRβ (Figure 8). The CNTFRα lacks transmembrane and cytoplasmic domains and is
attached to the cell membrane by a glycosyl-phosphatidylinositol anchor. The receptor
subunit exists in two functional forms, either bound to the membrane or soluble after cleavage
by phospholipidase c. CNTFRα has no enzymatic activity, but forms a functional complex
with CNTF that promotes its binding with gp130 and LIFRβ, ultimately leading to tyrosine
phosphorylation, STAT (signal transducers and activators of transcription) activation,
dimerisation and translocation to the nucleus, where they bind to specific DNA sequences,
leading to enhanced transcription of responsive genes, e.g. VIP, somatostatin, Substance P
and ChAT (Stahl and Yancopoulos, 1994; Stahl et al., 1995). Several lines of evidence
indicate that CNTF may be a powerful mitigator against to injury of the nervous system. In
experimental animals, CNTF has been delivered by direct infusion using osmotic pumps, by
daily injections, via implanted cells engineered to express CNTF or encapsulated in a polymer
membrane, and by viral vectors. In all cases, CNTF was shown to proserve striatal neurons in
a chemically-induced rat model of HD (Anderson et al., 1996; Emerich et al., 1996; Emerich
et al., 1997a; de Almeida et al., 2001). The neuroprotective effect of CNTF on GABAergic
striatal neurons was also tested in the primate lesion models QA and 3-NP (Emerich et al.,
1997b; Mittoux et al., 2000). In a genetic in vitro model, CNTF was also shown to protect
striatal neurons from death (Saudou et al., 1998).
This led to the initiation of a clinical trial in order to determine the effect of CNTF in HD
patients (Bachoud-Levi et al., 2000). In this trial, CNTF was delivered ex vivo by
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encapsulated BHK cells implanted into the lateral ventricle of HD patients. The trial has
demonstrated the feasibility of long-term delivery of CNTF in human brain with the
encapsulation technique. However, the diffusion of the factor from the ventricle to the
parenchyma is limiting as was shown in primates (Mittoux et al., 2000), therefore providing
only little benefit to the patients (Bloch et al., 2004) .
1.4.3. BDNF
Brain-derived neurotrophic factor (BDNF) was the second protein with neurotrophic activities
that isolated after the nerve growth factor (NGF) (Barde et al., 1982). Together with NGF,
NT-3, NT-4/5, it belongs to the family of neurotrophins, which act through the interaction
with two distinct receptors. All four bind to the p75 neurotrophin receptor (p75NTF) and to a
specific member of the tyrosine kinase (Trk) receptor family, the TrkB. Two alternative splice
variants of the TrkB receptor exist: a full-length and a truncated variant. The latter is thought
to act as dominant inhibitor and therefore to modulate the trophic effect of neurotrophin.
Binding of neurotrophin homodimers causes receptor homodimerization, followed by its
phosphorylation at several tyrosine residues (Figure 9). Various signaling cascades are then
activated: the PI3K/Akt kinase pathway, the mitogen-activated protein kinase MAPK/ERK
pathway and the PLC-γ1 pathway (Barbacid, 1994).
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Figure 9: BDNF and its receptors: mode of action
The schema shows how BDNF acts in the cell. The cellular actions of BDNF are mediated through two types of
receptors: a high-affinity TRKB and a low-affinity pan-neureotrophin p75 receptor. Binding of BDNF initiates
TRKB dimerization and transphosphorylation of tyrosine residues in its cytoplasmic domain. The
phosphotyrosine residues of TRKB receptors function as binding sites for recruiting specific cytoplasmic
signaling and scaffolding proteins. Binding of Shc (Src Homology domain-containing adaptor protein) results in
recruitment of a complex of adaptors like Grb2 and SOS, which activate Ras. Ras in turn activates the PI3K,
MEK1/2 pathway.
BDNF is produced by cortical neurons in layers V and VI, anterogradely transported, released
and finally taken up by GABAergic striatal neurons (Marty et al., 1997). It is found in the
striatum at a concentration of 7 ng/g of tissue, which is decreased by half in aged rats (Katoh-
Semba et al., 1998; Yurek and Fletcher-Turner, 2001). The receptor TrkB is expressed and is
present in both forms in the striatum. BDNF is a potent survival factor for striatal neurons
(Ventimiglia et al., 1995) and induces the differentiation of striatal GABA-, calbindin- and
DARPP-32 neurons (Nakao et al., 1995). BDNF and TrkB are upregulated after QA, 3-NP or
colchicine lesions in the striatum and might serve, therefore, as an endogenous
neuroprotective system (Alberch et al., 2004). BDNF knock-out mice die prematurely (Jones
et al., 1994; Ivkovic et al., 1997) and the cortical postnatal ablation of BDNF induces early
striatal dendrite deficits reminiscent of HD transgenic mice (Baquet et al., 2004). Intrastriatal
administration of BDNF protects striatal neurons from excitotoxicity in vivo (Martinez-
Serrano and Bjorklund, 1996; Bemelmans et al., 1999; Perez-Navarro et al., 2000b; Gratacos
et al., 2001b). BDNF may play a direct role in HD, since it is decreased in affected patients,
transgenic mice models and cell cultures (Zuccato et al., 2001). In addition, BDNF induces
neurogenesis in the adult brain. Therefore it could have the dual effect of being
neuroprotective and also promoting neurogenesis (Zigova et al., 1998; Pencea et al., 2001).
BDNF is therefore one of the interesting candidates for gene therapy strategies in HD because
of its implication in the disorder and its protective effects on striatal projection neurons.
However, its neuroprotective properties still need to be verified in genetic animal models of
HD.
1.5. DELIVERY OF NEUROTROPHIC FACTORS IN THE CNS
The systemic delivery of neurotrophic factors has major disadvantages. It is often associated
with side effects as their receptors are widely distributed in the organism and the proteins do
not cross the blood-brain barrier. Therefore direct CNS delivery is proposed to avoid the
limitations of systemic delivery. Recombinant protein delivery, especially of neurotrophic
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factors, has shown promising success in animal models of neurodegenerative diseases and is
currently being tested in clinical trials with GDNF for PD (Gil et al., 2002), CNTF for HD
(Bachoud-Levi et al., 2000) and NGF for AD (http://www.clinicaltrials.gov/ct/gui/show
/NCT00017940).
Several different strategies have been developed to directly deliver proteins in the brain. The
choice of method depends on the application, the delivery area, the treatment duration and the
balance of risks versus benefits. The delivery of GDNF with mechanical pumps has brought
new prospects to PD patients, although long-term problems could be associated with the
infusion device and the high amount of delivered GDNF. Alternatively, ex-vivo gene therapy
approaches could be designed to locally deliver neurotrophic factors from encapsulated cells
or a graft of engineered cells. Finally, gene therapy with viral vectors could bring an efficient
alternative to the issues of long-term delivery of protein in the CNS. In our studies we have
chosen the viral vector approach, because it was shown to efficiently infect striatal neurons
and constantly deliver proteins, which is particularly interesting for long-term experiments
with transgenic mice. Moreover, due to the small size of mice, the implantation of mechanical
devices in the brains would be very difficult to realize technically. In addition, viral vectors
have the valuable advantages that after production they can be stored for later use and that the
surgery is simple compared to other devices.
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1.5.1. Viral vectors for gene therapy
Gene therapy is a novel approach to treat diseases by directly modifying gene expression.
Thus, genes become the pharmaceutical agent and gene therapy the tool for drug delivery
(Kay et al., 2001). Replacement of defective genes, expression of novel genes or even
silencing of toxic genes can be considered. Although this may be seen as a simple concept,
this new technique implies technical, ethical and bio-safety concerns. The challenge is to
develop approaches for the delivery of genetic material to the target cells that operate in an
efficient, specific and safe way.
The feasibility and efficacy of gene therapy was demonstrated for the first time with the
clinical trial of a therapy for severe combined immunodeficiency (SCID) (Bordignon et al.,
1995; Bordignon, 1998; Cavazzana-Calvo et al., 2001; Aiuti et al., 2002). Bone-marrow stem
cells taken from the patient were genetically engineered to express the defective gene (ADA
or SCID) with viral vectors. The successful treatment of the first patients was much welcomed
in the scientific and medical community. The sudden and sad news of two treated children
who developed a leukemia-like disease turned this first trial into a general alarm against gene
therapy. Genetic analysis of the malignant cells showed that the gene was inserted in a locus
which activates oncogene LMO2 (Hacein-Bey-Abina et al., 2003a; Hacein-Bey-Abina et al.,
2003b; Cavazzana-Calvo et al., 2004) and the clinical protocol was inducing a clonal
selection. Thus the balance of risks and benefits has to be evaluated individually, because
gene therapy represents a life-saving treatment for most of the SCID children.
In vivo gene therapy for neurodegenerative diseases presents additional difficulties. The brain
is probably the organ that is the least accessible to therapeutic intervention. In addition, the
terminally differentiated state of neurons precludes the use of conventional retroviral vectors,
which require cell replication for stable integration into the genome. Several viral vectors
have been developed to overcome this barrier, such as viruses derived from the Herpes
Simplex Virus, the Adeno-associated Virus (AAV) and the Lentivirus (Lv). These last two
vectors have interesting properties for a long-term and sustained gene delivery in the brain.
The choice of adequate vector strictly depends on the therapeutic or experimental goal. High
transduction efficiency in the striatum combined with a large cloning capacity makes Lv the
ideal vector to model HD and to evaluate therapeutic strategies. On the other hand, AAVs
(serotype 2) have shown a high affinity for tyrosine hydroxylase (TH)-positive substantia
nigra neurons, which could be an advantage for PD therapy (Kirik and Bjorklund, 2003;
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Nakai et al., 2003). Moreover, the property of being retrogradely transported from the muscle
nerve terminal to the spinal cord makes this vector attractive for ALS (Kaspar et al., 2003).
Recently, a rabies-G pseudotyped equine infectious anaemia virus (EIAV) expressing VEGF,
which was injected in muscles and retrogradely transported to motoneurons in the spinal cord,
showed efficient gene delivery associated with behavioral improvement and survival of SOD-
1 transgenic mice (Azzouz et al., 2004).
1.5.2. Lentiviral vectors
Replication-defective and multiply attenuated lentiviral vectors have several features suitable
for gene delivery into neurons. They efficiently infect quiescent cells and long-term sustained
transgene expression is observed. Moreover, the absence of sequences encoding toxic viral
proteins and the large cloning capacity of about 9 kb (Naldini, 1998) makes them ideal for
gene therapy. Lentiviral vectors are therefore interesting for neurodegenerative disease
research, since they can be used not only to model genetic diseases (such as Parkinson’s
disease and Huntington’s disease (de Almeida et al., 2002; Lo Bianco et al., 2002; Kirik and
Bjorklund, 2003; Régulier et al., 2003)), but also to administer therapeutic molecules in
various animal models of these diseases (Kordower et al., 1999; Bensadoun et al., 2000;
Déglon et al., 2000; de Almeida et al., 2001; Lo Bianco et al., 2002; Palfi et al., 2002).
Figure 10: The four plasmids used to generate lentiviral vectors
The third generation of HIV-1-derived lentivirus vector is produced by cotransfection of four plasmids,
consisting of the split tat-less packaging vectors, the REV plasmid, the heterologous envelope vesicular somatitis
virus G-glycoprotein (VSV-G), and the improved SIN transfer vector.
Transfer vector
Packaging vectors
CMV polyA
CMV VSVG polyACMV REV polyA
POL
GAG RRE
TAT
LTR promoter Transgene SINWPRE
ψ
SD
PRO
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As human lentiviral vectors are derived from the HIV-1 virus, bio-safety is one of the major
concerns for potential gene therapy applications. Several strategies in vector design have been
applied to minimize the remaining risk and a first clinical trial is current underway with this
vector (Dropulic, 2004)(NIH 0107-488). Alternatively, equine (EIAV), simian (SIV) and
feline (FIV) viruses are developed as vectors to minimize the risk of viral genome
recombination with wild type HIV. The standard strategy is to delete viral genes that are not
essential for gene delivery. The essential genes are then divided in several plasmids (rev, gag-
pol, env) plus one plasmid containing the gene of interest, which is called transfer vector
(Figure 10). Deletion of the packaging sequence Ψ in the packaging plasmids will produce
vectors without viral genomes. Only the transfer vector will be packed in the viral particle. A
partial deletion of the 3’ LTR leads to the production of self-inactivating vectors (SIN) where
the promoter is inactivated.
This first generation of viral vectors was improved using several strategies. The wild-type
envelope gene (env) was deleted and replaced with a gene encoding the heterologus envelope
protein from the vesicular stomatitis virus (VSV-G), expressed in a separate plasmid. This
makes the viral vector more robust, allowing purification with ultracentrifuges and increasing
the host range. A significant increase in transduction efficacy is achieved by including the
central polypurine tract (cPPT), which increases nuclear translocation of the viral vector
genome (Follenzi et al., 2000; Sirven et al., 2000; Zennou et al., 2000). An enhanced
transgene expression is achieved upon introducing the Woodchuck post-transcriptional
regulatory element (WPRE), which stabilizes the RNA-protein complex enhancing protein
expression (Zufferey et al., 1999; Déglon et al., 2000). Finally, major efforts to design
regulated transgene expression single vectors are currently underway.
Figure 11: Lentiviral vector production
Upon transfection of all four plasmids into human 293T cells, high titers of replication-defective, self-
inactivating vectors are produced.
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The recombinant viruses are produced by transient transfection of human 293T cells (Figure
11). The viral vectors are produced by the cells and secreted in the medium. The viral vector is
concentrated by ultracentrifugation or purified by ultrafiltration. The preparation can then be
used for in vitro applications by just adding the viral preparation to the medium or it can be
delivered to animals. In both cases, the infection is an abortive process as the viral genome is
deleted in the recombinant Lv. Infected cells are therefore unable to produce new viral vectors
(Figure 12).
Figure 12: Lentiviral-mediated production of exogenous protein in a target cell
VSV-G pseudotype interacts with the membrane of the target cell (here a neuron) and allows entry to the
cytoplasm by the endocytic pathway (Aiken, 1997). The virion core is uncoated to expose the viral nucleoprotein
complex. The modified virion is reverse transcribed. This viron is also called a pre-integration complex in which
viral cDNA intermediates are synthesized and integrated into the host chromosome. The integration site within
the host cell genome appears to be random, althought a preference for kinked or distorted DNA has been
observed (Frankel and Young, 1998). The transgene can now be transcribed in the host cells. As the packaged
viron does not contain any encode for viral proteins, the virus itself will not be produced in the infected cell.
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1.6. AIMS AND STRATEGIES OF THIS THESIS
Despite major research efforts on Huntington’s disease (more than 3’000 Pubmed references
in the last 10 years), no clear pathological mechanisms and no validated treatment have been
proposed. To gain insight into the pathology, the main aim was to develop a new cellular
model of the disease, characterized by a general chronic and severe pathology in striatal
neurons, thus allowing an extensive dissection of the pathology with a large range of
technologies, spanning from immunocytochemistry, biological, enzymatic activity tests and
gene expression analysis. Once this goal was achieved, therapeutic strategies were evaluated
first in this cellular model, and then in genetic animal models.
To develop the new cellular model, primary rat striatal cultures were infected with lentiviral
vectors to express a mutant huntingtin fragment. The two-month survival of the culture
combined with the transgene expression in most of neuronal cells are both indispensable
elements, which allow the reproduction of major features of Huntington’s disease
neuropathology. Once the model was characterized, neuroprotective strategies were tested.
The effects of two neurotrophic factors CNTF and BDNF, were assessed. Both were
previously described to protect striatal neurons in other experimental paradigms. The success
of neuronal protection was then tested on genetic animal models, both transgenic mice and
lentiviral-mediated rat models showing neuronal death. Lentiviral vector injections in
parenchyma assered the long-term delivery of the trophic factors in the rodent striatum.
Neuronal protection was evaluated with behavioral and immunohistochemical analysis.
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2. PRIMARY STRIATAL CULTURES EXPRESSING MUTANT
HUNTINGTIN: CHRONICLE OF A FORETOLD DEATH
Submitted as:
Neuronal dysfunction and cell death in primary striatal cultures expressing a mutant
huntingtin fragment via a lentiviral vector
Diana Zala, Alexandra Benchoua, Emmanuel Brouillet, Anne D. Zurn, Patrick Aebischer and
Nicole Déglon
2.1. ABSTRACT
Several cellular models have been developed following the cloning of huntingtin (htt), the
gene that is mutated in individuals with Huntington’s disease (HD). However, none of these
models allows biochemical and molecular dissection of mutant htt-induced cell death in
striatal neurons, the most relevant cell type for HD pathology. In this study, we have used a
lentiviral vector expressing the first 171 amino acids of the mutant htt protein (htt171-82Q) to
generate a chronic model of HD in rat primary striatal neurons and reproduce the pathological
events leading to cell death. The transduction of primary cultures with lentiviral vectors
allowed the analysis of long-term cultures with more than 95% of neurons infected. The first
sign of pathology in cells expressing the htt mutant fragment was the appearance of nuclear
and neuritic inclusions at 4 weeks post-infection. These inclusions progressively accumulated
thereafter, with a concurrent loss of neurofilaments. By 8 weeks, the number of NeuN- and
MAP-2-positive cells was significantly lower in htt171-82Q-infected cultures than in controls.
The decrease in NeuN and MAP-2 positive cells was associated with a decrease of ubiquitin-
positive cells and an increase of TUNEL staining indicating neuronal loss. Cortical cultures
infected with the same vector accumulated numerous inclusions but showed no alterations in
the levels of NeuN or MAP-2 expression. Finally, co-transfection with htt171-82Q and
lentiviral vectors encoding the neurotrophic factors CNTF or BDNF prevented striatal
dysfunction and degeneration, but did not alter inclusion formation. This cellular model of
HD, which displays progressive and selective striatal pathology over a period of 2 months,
provides a flexible system for quantitative analysis and dissection of the intracellular
pathways underlying mutant htt-mediated cell death.
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2.2. INTRODUCTION
Huntington’s disease (HD) is a progressive, fatal, autosomal dominant disorder of the nervous
system characterized by uncontrolled movements, mood imbalance, depression, and dementia.
The mutation leading to HD has been identified as a glutamine expansion in the N-terminal
portion of htt (The Huntington's Disease Collaborative Research Group, 1993). In the brain,
htt is mainly expressed in neurons (Sapp et al., 1997). The striatum is the main site of
degeneration in individuals with HD, although other structures are affected at later stages
(Vonsattel et al., 1995). In vitro models of HD have been developed using various cell lines,
including those of neuronal origin (Cooper et al., 1998; Hackam et al., 1998; Liu, 1998;
Lunkes and Mandel, 1998; Li et al., 1999; Rigamonti et al., 2001; Zuccato et al., 2003),
transfected neuronal cultures (Saudou et al., 1998; Sanchez et al., 1999; Goffredo et al.,
2002), primary neurons from HD transgenic mice and striatal cell lines derived from knock-in
mice (Trettel et al., 2000; Petérsen et al., 2001a; Snider et al., 2003; Zeron et al., 2004). These
models have been used to identify intracellular pathways involved in HD pathology. Studies
suggest that mutant htt is cleaved by proteases (caspases, calpains, and aspartyl proteases) and
that the toxic N-terminal product containing the polyglutamine tract is translocated into the
nucleus where it forms inclusions, sequesters transcription factors and binds to several
essential proteins (Sanchez Mejia and Friedlander, 2001; Gafni and Ellerby, 2002; Lunkes et
al., 2002; Bates, 2003; Sugars and Rubinsztein, 2003). In addition, mutant htt aberrantly
interacts with proteins in the cytoplasm leading to caspase activation, mitochondrial toxicity,
and the formation of neuritic aggregates that block axonal transport (Ross, 2002;
Gunawardena et al., 2003). However, the function of wild type htt, the neuronal dysfunctions
induced by the CAG expansion, and the sequence of events leading to neuronal death are still
poorly understood.
To gain further insight into the pathological events induced by mutant htt, HD models suitable
for analytical studies and showing a progressive but severe striatal pathology are required.
Unfortunately, primary striatal cultures obtained from transgenic mice expressing mutant
huntingtin display subtle changes in intracellular pathways, but not cell death (Petérsen et al.,
2001a; Hermel et al., 2004; Zeron et al., 2004). In contrast, neuronal degeneration and cell
death have been detected in striatal cultures transfected with mutant htt fragments, but
transfection efficiency was too low to allow extensive biochemical analysis (Saudou et al.
1998). Thus, we have developed an in vitro model of HD by infecting E16 rat striatal neurons
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with a lentiviral vector encoding the first 171 amino acids of mutant (82Q) htt. The high
transduction rate and sustained transgene expression obtained with lentiviral vectors offers a
new opportunity to analyze mutant htt-induced cell death with cytological, molecular and
biochemical methods. In addition, the data gathered from this model can be rapidly validated
in vivo with the same gene transfer system (de Almeida et al., 2002; Régulier et al., 2003).
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2.3. MATERIALS AND METHODS
2.3.1. Cell cultures
Timed-pregnant Sprague Dawley rats (Charles Rivers Laboratories, Les Oncins; France) were
killed by CO2 inhalation and embryos (E16) were collected in a Petri Dish and placed on ice.
Dissections were performed under a stereomicroscope in ice cold dissection medium (DMX)
containing Ca2+- and Mg2+-free phosphate buffer saline (PBS), 0.6% D-Glucose, 1% Pen-
Strep (10000 U/ml, 10000 µg/ml), and 10mM HEPES (Invitrogen AG, Basel; Switzerland).
Ganglionic eminences or cerebral cortices were isolated, cut into pieces using forceps and
collected in a 15 ml Falcon tube. The medium and buffer were removed by decanting on ice.
The tissue was homogenized by repeated pipetting with a fire-polished Pasteur pipette in
DMX containing 1% bovine serum albumin (BSA) (Fluka, Buchs; Switzerland). Cells were
centrifuged at 4°C for 5 min at 1000 g and resuspended in 10 ml of glutamate-free Neurobasal
medium containing 1% B27 (Invitrogen) 1% Pen-Strep (10000U/ml, 10000µg/ml), 0.5mM L-
Glutamine and 15mM KCl. Cells were plated at a density of 150 000 cells/cm2 in multi-well
dishes coated with 20 µg/ml Poly-L-lysine (Sigma, Buchs; Switzerland). The cultures were
maintained in a humid incubator (5% CO2, 95% air at 37°C) and half of the medium was
changed weekly. Cultures were kept for up to 8 weeks. CNTF and BDNF treatments were
carried out by adding 50 ng/ml of the appropriate recombinant protein to the media 3 times a
week starting week 4.
2.3.2. Lentiviral vector production and infection
cDNAs encoding enhanced GFP (Clonetech, Palo Alto; USA), nuclear localized β-
galactosidase (nls-LacZ), human CNTF (murine immunoglobulin signal peptide [nucleotides
13-60, Genbank K00608] fused to the human CNTF cDNA [nucleotides 84-684, Genbank
NM000614] ), human BDNF (human pre-proNGF domain [nucleotides 170-532, Genbank
X52599] fused to the human BDNF [nucleotides 681-1040, Genbank X60201] ) and the first
171 amino acids of mutant human huntingtin fragments containing either 19 or 82 CAG
repeats (htt171-19Q/82Q) were cloned into the SIN-W-PGK transfer vector (Déglon et al.,
2000; de Almeida et al., 2001; Régulier et al., 2003). The viral productions were performed in
293T cells with a four plasmid system as described previously (Déglon et al., 2000; de
Almeida et al., 2001; Régulier et al., 2003).  The viruses were resuspended in (PBS) with 1%
BSA and matched for particle content of 1500 ng p24 antigen/ml as measurement by
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ELISA (Perkin Elmer Life Sciences; USA). The cell cultures were infected with lentiviral
vectors at ratio of 10 ng of p24 antigen/105 cells one day after plating (1 DIV). Co-infections
were carried out using two viral vectors, each at a ratio of 10 ng p24 antigen/105 cells. At 2
DIV, half of the medium was replaced with freshly prepared culture medium.
2.3.3. Immunostaining
Cell cultures were washed with cold PBS and fixed in 4% paraformaldehyde (Fluka) for 10
min at 4°C. Cultures were subsequently washed with PBS and then incubated in a blocking
solution of PBS supplemented with 10% normal goat serum (NGS) (Dakocytomation, Zug;
Switzerland) and 0.03% Triton X-100 (Sigma). The cells were then incubated overnight at
4ºC in blocking solution containing a primary antibody and then for 2h at room temperature
with secondary antibodies coupled to fluorophores (Jackson Immunoresearch Laboratories,
West Grove; USA) or biotin (Vector laboratories, Peterborough; UK). Cells incubated with
biotin-coupled secondary antibodies were further processed using the Vectastain Elite ABC
detection kit (Vector laboratories, Peterborough; UK) and diaminobenzidine
tetrahydrochloride, according to the manufacturer’s recommendations. The following
antibodies and dilutions were used: mouse monoclonal 2B4: 1/1000 (gift from Yvon Trottier,
CNRS/INSERM/ULP, Illkirch, France (Lunkes et al., 2002)), rabbit polyclonal EM48: 1/1000
(kindly provided by Dr. X. J. Li, Emory University School of Medicine, Atlanta, GA (Li et
al., 1999)), mouse monoclonal mEM48 (Chemicon International Inc., Temecula; USA), rabbit
polyclonal GFAP: 1/300 (Molecular Probes, Leiden; Netherlands), rabbit polyclonal Hsp70:
1/200 (Stress-Gene, San Diego; USA), rabbit polyclonal LacZ: 1/1500 (Promega, Madison;
USA), mouse monoclonal MAP-2: 1/600, mouse monoclonal NeuN: 1/400 (Chemicon
International Inc., Temecula; USA), mouse monoclonal NF160: 1/400 (Sigma Chemicals,
Deisenhof; Germany) and rabbit polyclonal Ubiquitin: 1/1000 (Dakocytomation, AG, Zug;
Switzerland). To detect endogenous and exogenous htt (2B4), cultures were pre-treated for 30
min with 1% cyanoborohydride (Fluka) and then incubated for 30 min in 0.4% Triton X-100
in PBS.
Confocal microscopy was performed using a Leica TCS SP2 AOB2 microscope (Heidelberg;
Germany). Cell cultures stained with NeuN or MAP-2 were counted using an Olympus CK40
microscope (Alberstland; Danemark) at a magnification of x20. At least eight fields of view
were counted for each of the samples stained with a given antibody and the mean number of
cells were calculated and normalized using non-infected cells from the same plate. Duplicates
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of three independent experiments were analyzed for each group.
2.3.4. Flow cytometry analysis of GFP expression and DNA fragmentation
GFP-infected cells (1x106 at 7 DIV) were treated with 1% Trypsin, 1 mM EDTA (Invitrogen)
for 15 min. A solution of 10% fetal bovine serum (FBS) was added to stop the reaction. The
cells were dissociated, centrifuged at 1500g for 10 min, resuspended in PBS, fixed with PBS
containing 2% paraformaldehyde (Fluka) for 10 min on ice, centrifuged at 1000g for 5 min
and resuspended in 500 µl of PBS. Their GFP content was then measured.
DNA fragmentation analysis was performed using the Cell Death FITC kit (Roche Pharma,
Basel; Switzerland). Trypsinization and fixation of the cultures were performed as described
for above for the GFP quantification. Cells were then permeabilized by incubation with 0.1%
saponin for 10 min at RT and processed for TUNEL staining according to the manufacturer’s
instructions. As controls, cells were processed for the TUNEL reaction in the absence of
transferase (negative control) or following pre-incubation with DNAse I (positive control) to
determine the gate of interest for FACS analysis. Cell counts were preformed on FACScalibur
cell sorter on four sister cultures and analyzed using the CellQuest software (BD Bioscience
Franklin Lakes; USA). Data from the TUNEL analysis were quantified by subtracting the
background counts obtained from analyzing non-infected cultures from the counts obtaining
with treated cultures.
2.3.5. Western Blot and ELISA
Cultures were treated with 1% Trypsin and 1 mM EDTA (Invitrogen) for 15 min and then
centrifuged for 10 min at 1000g. The pellets were lysed by a 30 min incubation on ice with
RIPA-modified lysis buffer (150 mM NaCl, 50 mM TRIS pH 8.0, 5 mM EDTA, 0.5% Triton
and 0.5% protease inhibitor cocktail (Sigma)) and vortexing every 10 min. The lysates were
centrifuged at 13,000 g for 30 min at 4°C, and the supernatants were stored at -80°C. Protein
concentrations were determined using the BCA protein Assay (Pierce, Rockford; USA). For
Western Blot analysis, proteins were denatured for 5 min by boiling in an SDS buffer (10%
sucrose, 1.2% SDS, 5% β-mercaptoethanol and 0.025% bromophenol blue). Protein extracts
were then subjected to SDS-PAGE on 15% acrylamide gels and electro-blotted onto
polyvinylidene difluoride membranes (Bio-rad, Hercules, CA, USA). Membranes were
incubated overnight at 4°C in 5% non-fat milk with primary antibodies (GFP: 1/1000
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(Molecular Probes), Hsp70 1/1000 (Stress-Gene, San Diego; USA), myc 1/1000 (Upstate
Biotech Chicago, IL) and NF160 1/1000 (Sigma)) diluted in TBS-T (20 mM Tris-HCl pH 7.6,
137 mM NaCl, 0.05% Tween 20) with % non-fat dry milk at 4°C. After the incubation for
1 hr at room temperature with a secondary horseradish-peroxidase conjugated antibody
(1/5000; Amersham), antigens were revealed by enhanced chemiluminescence using the
ECL+ kit (Amersham) according to the manufacturer’s instructions.
The concentrations of CNTF and BDNF were determined by ELISA (R & D, Abingdon, UK)
on media samples collected at 8 weeks and stored at -20°C until use. Samples were processed
accordingly to the manufacturer’s instructions. The detection limits were 8 pg/ml for CNTF
and 20 pg/ml for BDNF.
2.3.6. Statistical Analysis
Data are expressed as the mean +/- standard error of the mean (SEM). One-way ANOVA was
used to analyze the time course of ubiquitination. For the kinetic analysis of NeuN expression,
two-way ANOVA was performed with with independent variables of time factor (df = 3) and
group factor (df = 2). Post hoc analysis with LSD test was applied as a follow-up for the
significant differences shown by ANOVA for both time and dosage factors. A cut-off value of
p < 0.05 was used for statistical significance. Statistical analysis was performed using the
Statistica software version 5 (StatSoft, Tulsa, USA).
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2.4. RESULTS
2.4.1. GFP-expressing striatal neurons can be cultured for up to 8 weeks
We constructed a recombinant lentiviral vector expressing the GFP under the
phosphoglycerate kinase (PGK) promoter to assess the transfection efficiency of primary
striatal cultures. One week after infection, FACS analysis revealed that 92-94% of the cells
were GFP-positive (Figure 13A). Stable transgene expression (Figure 13B) and high neuronal
survival (Figure 13C) were observed for up to 8 weeks, allowing long-term analysis. Co-
infection of striatal cultures with two different vectors expressing GFP or nls-LacZ revealed
that most of the cells integrated at least two proviruses and expressed both reporter genes
(Figure 13E). These results show that this system can be used to co-express mutant htt and
either reporter or therapeutic genes with the aim of dissecting the intracellular pathways
involved in mutant htt toxicity.
The phenotype of the striatal cells was analyzed using the neuronal and astrocytic markers
NeuN and GFAP, respectively. At 2 weeks, 84±2% of the cell in the culture were NeuN-
positive and 8±2% were GFAP-positive. Figure 13D shows that in infected cultures, GFP-
expressing cells had a neuronal morphology and expressed NeuN. More than 95% of the
NeuN-positive cells expressed GFP, whereas GFP-expressing astrocytes were rarely observed
(Figure 13D). Confocal microscopy demonstrated the segregation between GFAP and GFP
labeling (Figure 13D). However, transgene expression in astrocytes was observed when the
cultures were infected with a vector containing the GFAP promoter (Figure 14). The PGK
promoter was chosen for all subsequent experiments to recapitulate the preferential expression
of huntingtin in neurons (The Huntington's Disease Collaborative Research Group, 1993;
DiFiglia et al., 1995; Landwehrmeyer et al., 1995; Ferrante et al., 1997).
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Figure 13: High transduction efficiency and long-term expression of the GFP transgene in striatal neurons
(A) The transduction efficiency of primary striatal neurons was quantified by FACS at one week post-infection
using a GFP-expressing vector. A shift in FITC-A fluorescence (relative to controls) was observed in 92-94% of
the GFP-infected cells. (B) Cultures infected at DIV 1 with a GFP-expressing vector were fixed 2 and 8 weeks
later to assess the expression of the reporter gene. (C) The long-term survival of striatal cultures was assessed
using the neuronal marker NeuN. No significant decreases in NeuN density were observed between 2 and 8
weeks post-infection (mean +/- SEM; p= 0.43) (D) The phenotype of GFP-infected cultures was analyzed using
the NeuN and GFAP markers. Most of the green fluorescent cells have neuronal morphology and express the
neuronal marker, NeuN. Confocal microscopy revealed that the GFP and GFAP markers were segregated,
indicating that astrocytic expression did not occur. (E) Striatal cultures were co-infected at DIV 1 with two
independent vectors expressing the GFP and nls-LacZ reporter genes and fixed 2 weeks later. NeuN and LacZ
were detected by immunostaining and fluorescence was detected directly. The merged picture shows that a high
proportion of infected neurons express both transgenes.
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Figure 14: Lentiviral-mediated expression in astrocytes
Primary striatal cultures were infected at DIV 1 with a lentiviral vector encoding nuclear LacZ (nls-LacZ) under
the control of the GFAP promoter. Cultures were fixed at weeks 2 and stained for LacZ, GFAP and DAPI. The
merged picture shows LacZ staining in a GFAP-positive cell.
2.4.2. Mutant htt accumulates in neurons and forms nuclear and neuritic
inclusions
To model HD in vitro, we infected striatal cultures with a lentiviral vector encoding htt171-
82Q. Non-infected cultures or cultures infected with htt171-19Q, GFP were used as controls.
Expression of mutant htt was detected using the 2B4 antibody, which recognizes the N-
terminal part of both endogenous rat htt and human htt171-19/82Q (Lunkes et al., 2002)
(Figure 15A). The transgene was expressed in most neurons and progressively accumulated
over time (Figure 15A). At 8 weeks post-infection, nuclear and neuritic inclusions were
present in the majority of the htt171-82Q-infected neurons (Figure 15A). Human htt171-
19/82Q expression was confirmed by Western blot analysis using an antibody recognizing the
myc epitope located at the N-terminus of the htt-171-19/82Q fragments. Fragments with
molecular weights corresponding to those predicted for htt-171-19/82Q fragments, were
present at 6 weeks post-infection (Figure 15B). Interestingly, mutant htt171-82Q was more
abundant than the wild type htt171-19Q protein. The progressive accumulation of the mutant
htt protein and the relative abundance of this protein compared to wild type suggest that
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proteosomal degradation of mutant htt is impaired (Jana et al., 2001).
Figure 15: Expression of htt in striatal cultures and formation of htt inclusions
(A) Control or infected (GFP, htt171-19/82Q) striatal cultures were fixed at 2 and 8 weeks post-
infection and stained with the 2B4 antibody recognizing the N-terminal part of htt. Note the level of
endogenous rat huntingtin staining in control and GFP-infected cells. Wild type human htt171-19Q
fragment is present in the cytoplasm of neurons and does not lead to the formation of aggregates,
whereas mutant htt171-82Q progressively forms nuclear (V) and neuritic aggregates (*). (B) Western
blot analysis using the myc antibody showed that htt171-19/82Q was present at 6 weeks post-infection
and that mutant htt fragment accumulated in the cells. Coomassie Blue (c.b.) staining is shown as a
control to assess protein loading.
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2.4.3. Mutant htt leads to the progressive formation of ubiquitinated nuclear
inclusions
The presence of ubiquitinated nuclear inclusions in neurons is a typical feature of HD. We
therefore monitored the appearance of these aggregates over time. As expected, ubiquitin-
positive inclusions were not detected in the GFP- or htt171-19Q-infected cultures. No
inclusions were present in the htt171-82Q-infected cultures up to 2 weeks post-infection
(Figure 16B). At 4 weeks, 31±3% of neurons had at least one ubiquitinated nuclear inclusion.
Figures 3A and C show the distribution and variability in the number and size of the nuclear
inclusions in mutant htt-infected cells. After 6 weeks, the proportion of ubiquitin-positive
inclusions reached 56±3% (Figure 16B). Between 6 and 8 weeks, this percentage declined to
46±2%, probably as a result of neuronal death. A subset of mEM48-positive nuclear
inclusions were not labeled with the ubiquitin antibody at 6 weeks (Figure 16B; 63±3% of
neurons had mEM48-positive inclusions vs. 56±3% with ubiquitin-positive inclusions).
Similar results have been obtained previously (Gutekunst et al., 1999).
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Figure 16: Progressive appearance of ubiquitinated inclusions
(A) Striatal cultures infected with htt171-82Q were fixed at 6 weeks post-infection and immunostained for NeuN
and ubiquitin. The merged picture at high magnification shows the nuclear inclusions and the abundant of
neuritic aggregates in the neurons. (B) Striatal cultures (n=6 per time point) infected with htt171-82Q were
immunostained for ubiquitin and the number of neurons containing ubiquitin-positive nuclear inclusions was
quantified. The graph shows that the appearance of nuclear aggregates in the striatal cultures was progressive.
Note: inclusions were not present at 2 weeks, ubiquitin-positive inclusions then appeared gradually and reached
56±3% at 6 weeks, after which the number declined to reach 46±2% at 8 weeks. This decline was probably a
consequence of neuronal degeneration. Values are the mean +/-SEM and * represents values for which p< 0.05).
The insert shows a confocal image of nuclear inclusions labeled using the 2B4 (red) and ubiquitin (green)
antibodies and fluorescent-marker conjugated secondary antibodies. (C) Representative pictures showing the
heterogeneity of nuclear ubiquitinated inclusions co-localized with DAPI-stained chromatin.
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2.4.4. Presence of dystrophic neurites and induction of a stress response
Nuclear and neuritic htt inclusions have been reported in the brains of humans with HD
(DiFiglia et al., 1997). To analyze the appearance of aggregates in neuronal processes, htt171-
82Q-infected cultures with double-labeled with htt and neurofilament antibodies. The first
neuritic inclusions were visible at 4 weeks post-infection and were often associated with a
decrease in neurofilament immunoreactivity, 4 weeks post-infection (Figure 17A).
Immunostaining and Western blot analysis revealed that this reduction in neurofilament
expression was more pronounced at 6 weeks post-infection (Figure 17A). This down-
regulation appeared to be specific to the neurofilament class of structural proteins, as levels of
α- and β- tubulin staining were not modified by the expression of htt171-82Q (Figure 18). As
previously reported (Parker et al., 2001), the neuritic inclusions led to aberrant enlargement
and swelling of the neurites in which they occurred (Figure 17C). This phenomenon was also
observed in cultures co-infected with vectors encoding GFP and htt171-82Q (Figure 17B).
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Figure 17: Presence of dystrophic neurites
(A) Striatal cultures infected with htt171-82Q were fixed at 4 weeks post-infection and stained for
neurofilament (NF antibody) and huntingtin (EM48 antibody). The merged image shows that NF
immunoreactivity is reduced in neurites with htt aggregates (see arrows). Immunostaining and Western
blot analysis show that this reduction in NF expression is more pronounced at 6 weeks. Pictures taken
at the same exposure reveal the drastic down-regulation of NF expression in htt171-82Q infected cells
compared to that in control cultures. Western blot analysis using antibodies raised against NF
confirmed this reduction at 6 weeks post-infection. (B) Confocal images of GFP fluorescence in
neurites stained for ubiquitin (red), for NF (blue). Striatal cultures co-infected with lentiviral vectors
expressing htt 171-82Q or GFP were fixed at 6 weeks post-infection to illustrate the segregation
between neuritic inclusions (*) and the GFP-compartment. (C) Striatal cultures infected with htt171-
82Q were fixed at 8 weeks post-infection and immunostained for htt with the 2B4 antibody. Analysis
revealed swelling induced by the formationof neuritic inclusions.(*) inclusions in htt171-82Q neurons
while the over-expression of wild-type htt fragment was not associated with the formation of
inclusions as was illustrated in Fig. 2A (V = nuclear inclusions).
Figure 18: Mutant htt has no effect on α- and β- tubulin expression
Primary striatal cultures were infected at DIV 1 with a lentiviral vector encoding htt 171-82Q or htt 171-19Q.
Cultures were fixed at 6 weeks post-infection and stained for α - or β -tubulin and ubiquitin. The
photomicrographs show that mutant htt inclusions do not alter α- or β-tubulin expression.
Accumulation of misfolded proteins induces a stress response and the co-localization of
chaperones with inclusions has been reported in autopsy material from the brains of humans
with polyglutamine diseases and in HD transgenic mice (Cummings et al., 1998). In striatal
neurons expressing mutant htt, the appearance of the first inclusions at 4 weeks was
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associated with an increase in Hsp70 staining.
Figure 19: Stress response to mutant htt
(A) Striatal cultures infected with htt171-19Q and htt171-82Q were fixed at 4 weeks post-infection and stained
for Hsp70. The up-regulation of Hsp70 in striatal cultures infected with htt171- 82Q suggested production of the
mutant protein induced a stress response. No alterations in Hsp70 levels were observed in cultures infected with
the wild type htt fragment. This increase in of Hsp70 chaperone expression was confirmed by western blot. (B)
Hsp70 to co-localizes with nuclear inclusions (2B4 staining) but not with neuritic aggregates at 6 weeks post-
infection.
This up-regulation was confirmed by Western blot analysis (Figure 19A). Double labeling of
Hsp70 and htt revealed co-localization of the two proteins in nuclear, but not neuritic,
inclusions (Figure 19B). Interestingly Hsp27 and Hsp40 were not detected in aggregates of
either type (Figure 20).
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Figure 20: Hsp27 and Hsp40 do not co-localize with htt inclusions
Primary striatal cultures were infected at DIV 1 with a lentiviral vector encoding htt171-82Q. The cultures were
fixed at 6 weeks post-infection and stained for htt, Hsp27 or Hsp40. The photomicrograph shows that the
chaperones do not co-localize with the nuclear and neuritic htt inclusions (2B4-labeled).
2.4.5. Chronic expression of mutant htt induced a slow neurodegenerative
process leading to cell death
We evaluated the neuronal dysfunction induced by the expression of mutant htt in the striatal
cultures by staining with a neuronal marker (NeuN) and then counting the number of NeuN-
positive cells (Figure 21A). No differences were detected between control (GFP) and infected
(htt171-19/82Q) cultures at 2 and 4 weeks post-infection, demonstrating that viral vector
infection was not toxic. A 21±4% reduction in the number of NeuN-positive neurons was
observed for cultures expressing mutant htt at 6 weeks post-infection. This decline continued
during the following two weeks, leading to a 48±3% reduction in NeuN-positive cells. This
neuronal pathology was confirmed using a second neuronal marker, MAP-2 (Figure 21B): a
33±1% reduction in the number of MAP-2-positive cells was observed at 8 weeks. To
discriminate between neuronal dysfunction and cell death, striatal cultures were harvested at 8
weeks and stained using the TUNEL method. DNA fragmentation was analyzed in situ by
56
FACS. The number of cells containing fragmented chromatin was significantly higher in
htt171-82Q-infected cultures than in htt171-19Q-infected cultures (Figure 21C). Our data
indicate that the lentiviral-based expression of htt171-82Q in primary striatal cultures induced
a slow and progressive neuropathology, characterized by the presence of neuritic and nuclear
inclusions, and alterations in the expression of neuronal markers. Cell death occurred between
6 and 8 weeks after infection.
Figure 21: Kinetics of neuronal dysfunction and cell death
(A) Striatal cultures (n=6) infected with GFP, htt171-19/82Q and non-infected cultures were fixed at 2, 4, 6, 8
weeks post-infection and stained for NeuN. Neuronal dysfunction was assessed by counting the number of
NeuN-positive cells and values were normalized against those obtained for control cultures. A progressive
decrease in the number of NeuN-positive cells started at 6 weeks post-infection in the htt171-82Q-infected
cultures. (B) The neuronal dysfunction in striatal neurons expressing mutant htt was confirmed by MAP-2
immunostaining (8 weeks post-infection). (C) Cell death was quantified at 8 weeks using TUNEL-stained
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samples. The number of TUNEL-positive cells was significantly higher in the htt171-82Q expressing cultures.
2.4.6. Cortical neurons are resistant to mutant htt-induced cell death
The striatum is the main site of HD pathology but other structures are affected during later
stages of the disease. Thus, striatal neurons would be expected to be more sensitive to mutant
htt infection than neurons from other brain structures. We addressed this issue by dissecting
cortical cultures and infecting them with the htt171-82Q vector. The GFP and htt171-19Q
vectors were used as controls and results were compared those obtained with the infected
striatal cultures. As described above for the striatal neurons, the majority of NeuN-positive
cortical cells expressed the GFP reporter gene (Figure 22A; Figure 13A). In addition, nuclear
and neuritic htt inclusions were observed in the cortical neurons at 6 weeks (Figure 22B).
However, in contrast to the result obtained with the striatal cultures, no alteration in the
number of NeuN and MAP-2 cells was observed at 8 weeks in the cortical cultures (Figure
22C-D), despite the presence of nuclear aggregates in 63±1% of the cortical neurons (Figure
22B).
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Figure 22: Study htt toxicity in cortical neurons
(A) Cortical cultures infected with a lentiviral vector expressing the GFP were fixed at 6 weeks post-
infection and stained for NeuN and GFP. The transduction rate was high and the transgene expression
stable in NeuN-positive cortical cells. (B) Cortical cultures infected with htt171-82Q were fixed at 8
weeks post-infection and the formation of nuclear (V) and neuritc (*) inclusions was revealed by
huntingtin immunostaining. (C) Htt-induced cortical dysfunction was assessed using NeuN and MAP-
2 immunostaining (n=6). (D) Infection with htt171-82Q did not effect the expression of these neuronal
markers in the cortical cultures, despite the presence of numerous htt aggregates.
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2.4.7. Neuroprotective effects of CNTF and BDNF
To further validate our model, two trophic factors that prevent mutant htt-induced toxicity in
an acute in vitro model (Saudou et al., 1998) and in animal models of HD (Emerich et al.,
1997a; Bemelmans et al., 1999; de Almeida et al., 2001) were tested. Two delivery systems
were compared: the addition of recombinant proteins and lentiviral-mediated administration.
In the first set of experiments, recombinant CNTF and BDNF (50ng/ml) were added to
control and htt171-19/82Q cultures several times per week between weeks 4 and 8. At 4
weeks post-infection, the culture is at the dysfunctional stage, with an accumulation of htt
inclusions and a reduction in neurofilament expression but no cell death. No alteration in the
number of NeuN-positive cells was found 8 weeks, indicating that both CNTF and BDNF
prevented striatal degeneration (Figure 23A). In the second set of experiments, cultures were
first infected with lentiviral vectors encoding either wild type or mutant htt and then, 4 weeks
later, with vectors encoding CNTF, BDNF or GFP. NeuN quantification indicated that the
CNTF and BDNF delivered by the lentiviral vectors rescued neurons from mutant htt-induced
toxicity (Figure 23B). Trophic factor secretion was analyzed by ELISA in media collected
from 8-week old cultures. The supernatant of the htt177-19/82Q-infected neurons contained
140-270 pg/ml of BDNF and 25-30 ng/ml of CNTF (Table 1). The percentage of neurons with
ubiquitinated nuclear inclusions was higher in CNTF- and BDNF-treated cultures than in
controls (38±2% htt171-82Q/GFP; 68±2% htt171-82Q/CNTF; 82Q/CNTF; 64±4% htt171-
82Q/BDNF; p<0,005 GFP vs CNTF and BDNF) (Figure 23C). These results are consistent
with those of Saudou et al. 1998.
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Figure 23: Protection of CNTF and BDNF
(A) Primary striatal cultures (n=6) infected either with htt171-19Q or htt171-82Q were treated every other day,
starting from week 4, with 50 ng/ml of recombinant CNTF, BDNF or PBS (vehicle control). (B) In a second set
of experiments, CNTF and BDNF were produced from lentiviral vectors. Cultures (n=6) were infected at 4
weeks with lentiviral vectors encoding GFP, CNTF or BDNF. BDNF and CNTF prevented the down-regulation
of NeuN at 8 weeks post-infection in both sets experiments. (C) The formation of htt inclusions was assessed
using the EM48 antibody. Inclusion formation was not affected by these trophic factors.
Group   BDNF [pg/ml] CNTF [ng/ml]
htt 171-19Q + GFP BL BL
htt 171-82Q + GFP BL BL
htt 171-19Q + BDNF 270 ±  37 BL
htt 171-82Q + BDNF 149 ±  26 BL
htt 171-19Q + CNTF BL 30  ± 15
htt 171-82Q + CNTF BL 26  ± 10
Table 3: Lentiviral mediated release of CNTF and BDNF
Primary striatal cultures were infected at DIV1 with lentiviral vectors expressing htt171-19Q or htt171-82Q.
Four weeks later, the cultures were infected with lentiviral vectors expressing CNTF, BDNF or GFP (control).
Media were collected (n=10) at 8 weeks post-infection and the concentration of trophic factors was measured by
ELISA [pg/ml] (BL: background level; * p< 0.05, φ p = 0.5)
] ∗
] φ
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2.5. DISCUSSION
To recapitulate the sequence of events underlying mutant htt cell death, we have developed a
chronic model of HD in primary striatal cells, the neuronal subpopulation predominantly
affected in HD. The pathology associated with lentiviral-mediated over-expression of mutant
htt was characterized by three distinct phases: i) mutant htt progressively accumulated during
the first three week post-infection but cells showed no sign of neuropathology; ii) htt
inclusions and neuronal dysfunctions appeared between weeks 4 and 6; iii) finally cell death
occurred between weeks 6 and 8. The slow progression of the pathology, compared to
existing in vitro models of HD, provides an extended window of time for dissecting the
pathology of htt-induced toxicity and for discriminating the cascade of events leading to
striatal cell death. In addition, the high transduction efficiency obtained with lentiviral
vectors allows unlimited amounts of material to be generated for quantitative analysis of HD
pathology using molecular and biochemical approaches.
The htt-induced toxicity observed in our model system is consistent with that found in an in
vivo study using the same lentiviral-mediated gene transfer system in adult rats. In both
cases, striatal degeneration was slow and progressive (de Almeida et al., 2002). The chronic
and severe neuropathology observed in the htt 171-82Q-infected cells in our study may be
related to preferential integration of lentiviral vectors into transcriptionally active
chromosome sites (Schroder et al., 2002; Wu and Marsh, 2003) and the use of the PGK
promoter. Previous studies demonstrate that the level of htt expression is an important factor
in the generation of in vitroand in vivo HD models. For example, studies in transgenic mice
found no differences in survival rates between striatal cultures derived from wild type and
mutant (R6/2 and YAC72) littermates (Petersen et al., 2001; Zeron et al., 2004). In another
study, primary neurons transfected with a plasmid expressing mutant htt using the calcium
phosphate method degenerated after a few days as a result of very high transgene expression
(Saudou et al., 1998).
Neuritic and nuclear inclusions appeared 4 weeks after infection of striatal neurons with
mutant htt. The presence of htt aggregates in processes was associated with a dramatic
reduction in neurofilament expression, whereas α- and β-tubulin levels were unaffected.
These data support the findings that axonal transport and synaptic function are disrupted in
HD patients and the suggestion that this distruption may contribute to neuronal dysfunction
and cell death (Gunawardena et al., 2003). Cytoplasmic htt aggregates mainly accumulate in
the deep layers of the cortex and GABAergic neurons of the striatum in HD patients and
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the appearance of neuritic aggregates correlates with the development of neuropathological
symptoms (DiFiglia et al., 1997; Gutekunst et al., 1999; Kuemmerle et al., 1999). According
to Gunawardena et al. (2003), htt toxicity contributes to early HD neuropathology by one of
two non-exclusive mechanisms: through its effects on axonal transport or as a result of
nuclear accumulation of mutant htt. We showed that mutant htt was present in both
compartments in this lentiviral-based model of HD and our results suggested that over-
expression of this protein activated various intracellular pathways that led to the degeneration
of striatal neurons. NeuN, MAP-2 and neurofilament expression was down-regulated by 6
weeks post-infection, whereas that of Hsp70 was unregulated in the striatal neurons
expressing mutant htt. Several studies have demonstrated that translocation of mutant
huntingtin to the nucleus alters the activity of transcription factors (Nucifora et al., 2001;
Chai et al., 2002; Schaffar et al., 2004) and disrupts gene expression patterns (Luthi-Carter et
al., 2000; Steffan et al., 2000; Wyttenbach et al., 2001; Chan et al., 2002; Dunah et al., 2002;
Sipione et al., 2002). Preliminary DNA-microarray data on 6-week-old cultures indicate that
changes in the level of gene expression occur prior to striatal cell death and confirm the
alterations in neurofilament and Hsp70 expression reported in this study (unpublished data).
Previous studies have shown that Hsp production is also stimulated in cells expressing
mutant htt or an androgen receptor (Stenoien et al., 1999; Kobayashi et al., 2000) and in 30-
35-weeks-old R6/1 HD transgenic mice (Jana et al., 2000). This stress response may affect
polyglutamine pathogenesis and relieve neuronal dysfunction. Consistent with this view, the
over-expression of various chaperones reduces aggregate formation and cell death in vitro
(Cummings et al., 1998; Chai et al., 1999; Stenoien et al., 1999; Jana et al., 2000; Kobayashi
et al., 2000; Wyttenbach et al., 2000; Wyttenbach et al., 2002). We found that Hsp70 co-
localized with the htt nuclear inclusions, whereas no co-localization was observed with
neuritic inclusions. The biological relevance of this localization pattern is unknown (Jana et
al., 2000; Li et al., 2001).
The number of nuclear inclusions was highest in the htt 171-82Q-infected striatal neurons at
6 weeks post-infection, with 56±3% ubiquitin-positive and 63±3% mEM48-positive striatal
neurons. As more than 95% of the neurons expressed htt171-82Q, these data suggest that
some infected striatal neurons did not develop nuclear inclusions. This could be due to
variability in the levels of htt expression between cells. We have previously shown that
inclusion distribution is dose-dependent: neuropil aggregates were the most frequently
observed form of inclusion in the striatum of rats injected with a vector expressing low levels
of htt171-82Q, whereas nuclear inclusions predominated in neurons expressing high levels of
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mutant htt (de Almeida et al., 2002). Thus, infected striatal neurons expressing low levels of
mutant htt would be expected to develop neuritic aggregates. The high proportion of neuritic
aggregates obtained in primary striatal neurons infected with the htt171-82Q vector
compared to the in vivo data in adult rats (de Ameida et al. 2002) suggest that the PGK
promoter is less potent in vitro or that striatal cultured neurons are more prone to develop
neuritic inclusions in vitro. Detailed analysis of aggregate formation between 3 and 4 weeks
post-infection and quantitative analysis of htt expression in neurons with nuclear or neuritic
aggregates should provide additional information. Alternatively, sensitivity to htt aggregation
and htt toxicity may differ between neuronal subpopulations. In HD brains, htt aggregates are
abundant in cortical neurons but remain relatively rare in the striatum despite a severe
degeneration in this structure (Heinsen et al., 1994). We addressed this issue by investigating
the effects of mutant htt in cortical cultures. Mutant htt over-expression had no effect on
cortical neuron survival rates up to 8 weeks post-infection, despite the fact that the
percentage of cells with inclusions was higher for cortical neurons than for striatal neurons
(63±1% vs. 46±2%; p <0.05). The presence of inclusions in 64-68% of the CNTF/BDNF-
treated striatal neurons at 8 weeks post-infection, however, suggests that the kinetics of
aggregate formation are similar in both subpopulations. Thus, these data suggest that the
selective degeneration of striatal neurons is an intrinsic property of these neurons and that
this vulnerability is independent of corticostriatal input. Differences in htt protein processing
or to cell-type specific factors may account for this differential susceptibility. Lentiviral-
mediated delivery of mutant htt may therefore be a useful tool for in vitro and in vivo studies
aiming to determine the relative contribution of striatal and cortical compartments in HD
pathogenesis. Similarly, this method may also be useful for studies investigating the
molecular basis of the selective sparing of NADPH-d- andcholine-acetyltransferase- choline-
acetyltransferase-positive interneurons and the differential susceptibility of projecting striatal
neurons expressing enkephalin and those expressing substance P (Ferrante et al., 1985;
Graveland et al., 1985; Behrens et al., 1996).
Interest in the therapeutic potential of neurotrophic factors for HD patients had been renewed
by recent evidence suggesting a link between the production of BDNF and htt (Zuccato et al.,
2001; Alberch et al., 2004). Huntingtin was shown to regulate BDNF transcription and
vesicular transport (Ferrer et al., 2000; Zuccato et al., 2001; Gauthier et al., 2004). Evidence
that BDNF influences HD pathology was also obtained from studies of the offspring
generated by cross-mating HD transgenic mice (R6/1) and BDNF+/- mice: an early onset of
motor deficits and a lack of DARPP-32 expression in the striatum were observed in the
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double transgenic mice (Canals et al., 2004). The administration of BDNF as well as other
neurotrophic factors has been shown to enhance the survival rate of GABAergic neurons in
drug-induced models of HD (Alberch et al., 2004). However, data on the potential
therapeutic benefits of this type of treatment in genetic models of the disease and in HD
patients is limited (Saudou et al., 1998; Bachoud-Levi et al., 2000; Zala et al., 2004). In
addition, the intracellular signaling cascades mediating these neuroprotective effects are still
poorly defined. Recent data suggest that CNTF-mediated activation of astrocytes may alter
energy metabolism and neuronal function and thus contribute to the neuroprotective effect of
this molecule (Escartin et al., 2004). It still needs to be established whether the
administration of these molecules in the striatum of HD patients will delay the progression of
the disease.
In summary, this study demonstrates that infection of striatal cultures with a lentiviral vector
encoding mutant htt induces a pathology replicating the prominent features of HD. The
pathology observed was chronic, progressive and striatal neuron-specific. This cellular model
provides a versatile and unique tool for quantitative and mechanistic analysis that will be
particularly useful for further dissecting HD pathology, screening therapeutic candidates and
analyzing the intracellular mechanisms associated with the neuroprotective effects of various
agents.
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3. LONG-TERM EXPRESSION OF CNTF IN THE STRIATUM OF
HD MICE
Published as:
Evaluation of long-term effects of lentiviral-mediated CNTF delivery in the striatum of wild-
type and HD transgenic mice.
Zala, D., Bensadoun,  JC., de Almeida, L.P., Leavitt, B.R., Gutekunst, C.A., Aebischer P.,
Hayden, M., and Déglon N. (2004). Exp Neurol 185: 26-35
3.1. ABSTRACT
Ciliary Neurotrophic Factor (CNTF) has been shown to prevent behavioral deficits and
striatal degeneration in neurotoxic models of Huntington’s disease (HD) but its effect in a
genetic model has not been evaluated. Lentiviral vectors expressing the human CNTF or LacZ
reporter gene were therefore injected in the striatum of Wild-type (WT) and transgenic mice
expressing full length huntingtin with 72 CAG repeats (YAC72). Behavioral analysis showed
increased locomotor activity in 5-6 month old YAC72-LacZ mice compared to WT-LacZ
animals. Interestingly, CNTF expression reduced the activity levels of YAC72 mice compared
to control animals. In both WT and YAC72 mice, CNTF expression was demonstrated in
striatal punches up to a year after lentiviral injection. Stereological analysis revealed that the
number of LacZ and DARPP-32-positive neurons were decreased in YAC72-LacZ mice
compared to WT-LacZ animals. Assessment of the benefit of CNTF expression in the YAC72
mice was, however, complicated by a down-regulation of DARPP-32 and to a lesser extent of
NeuN in all mice treated with CNTF. The expression of the neuronal marker NADPH-d was
unaffected by CNTF, but expression of the astrocytic marker GFAP was increased. Finally, a
reduction of the number of striatal dark cells was observed in YAC mice treated with CNTF
compared to LacZ. These data indicate that sustained striatal expression of CNTF can be
achieved with lentiviruses. Further studies are, however, needed to investigate the
intracellular signaling pathways mediating the long-term effects of CNTF expression on
dopamine signaling and glial cell activation and how these changes may affect HD pathology.
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3.2. INTRODUCTION
Huntington’s disease is a fatal dominant disorder characterized by a selective neuronal loss in
the striatum and to a lesser extent in the cortex (Vonsattel and DiFiglia, 1998). The disorder is
caused by an expansion of a CAG repeat tract in the HD gene (The Huntington's Disease
Collaborative Research Group, 1993) which can be used to genetically identify pre-
symptomatic individuals who are at-risk for developing the disease (Andrew et al., 1993).
Initiation of therapeutic interventions prior to the onset of clinical symptoms and neuronal
degeneration can therefore be envisaged. Over the last few years, neuroprotective strategies
based on the use of neurotrophic factors have been developed, and significant rescue of
striatal neurons associated with behavioral improvement were observed in drug-induced
models of HD (Frim et al., 1993; Anderson et al., 1996; Emerich et al., 1996; Araujo and Hilt,
1998; Volpe et al., 1998; Bemelmans et al., 1999; Mittoux et al., 2000; Perez-Navarro et al.,
2000a).
CNTF (Ip and Yancopoulos, 1996), a member of the cytokine family, has been shown to
prevent behavioral deficits and striatal degeneration in quinolinic acid-lesioned rats and
primates (Anderson et al., 1996; Emerich et al., 1996; Emerich et al., 1997a; de Almeida et
al., 2001). Recently, we have further investigated whether CNTF could reduce neuronal
dysfunction and neurodegeneration in monkeys chronically treated with 3-nitropropionic acid
(3-NP) (Mittoux et al., 2000). This study demonstrated that the intracerebral and continuous
delivery of CNTF at the time of appearance of striatal dysfunction and motor/cognitive
symptoms, not only prevents neuronal degeneration, but also alleviates functional deficits.
Moreover, Saudou and collaborators have demonstrated that CNTF rescues primary rat
striatal cultures from cell death caused by the expression of a mutant htt fragment (Saudou et
al., 1998). This in vitro study suggests that CNTF might alter the degeneration of GABAergic
neurons in a genetic model of the disease.
In the present study, we have assessed the effect of long-term CNTF delivery in wild-type
mice and HD YAC transgenic mice expressing full-length htt with 72 CAG repeats (Hodgson
et al., 1999). These animals show electrophysiological abnormalities at 6 months, a mild
hyperkinetic movement disorder with a significantly increased activity between 5 and 9
months. By 12 months of age, these mice display an increase in the number of striatal dark
cells as measured by toluidine blue staining (Hodgson et al., 1999). Lentiviral vectors were
used to achieve local and long-term delivery of CNTF in the brain while avoiding side effects
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associated with systemic administration (Abicht and Lochmuller, 1999). Lentiviruses
expressing LacZ or human CNTF were bilaterally injected into the corpus striata of 4 month
old YAC72 mice and wild-type littermates. Behavioral analyses were performed during the
entire experiment to monitor the progression of the disease. Finally, at 13 months of age, the
animals were sacrificed and their brains processed to assess the effects of long-term CNTF
expression.
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3.3. MATERIAL AND METHODS
3.3.1. Lentiviral vector production
The cDNA coding for a nuclear-localized ß-galactosidase (LacZ) and the human CNTF
(Aebischer et al., 1996) were cloned in the SIN-W-PGK transfer vector (Déglon et al., 2000;
de Almeida et al., 2001). The packaging construct and the vesicular stomatitis virus G protein
(VSV-G) envelope used in this study were the pCMVΔR-8.92, pRSV-Rev and pMD.G
plasmids (Dull et al., 1998; Hottinger et al., 2000; Naldini et al., 1996). The viral particles
were produced by transient transfection of 293T cells as previously described (Hottinger et
al., 2000). LacZ- and CNTF-expressing viruses were resuspended in phosphate buffered
saline (PBS) with 1% bovine serum albumin and matched for particle content of 100'000 ng
p24 antigen /ml as measurement by ELISA (Perkin Elmer Life Sciences, MA, USA).
Figure 24: Schematic representation of the four plasmids used for the production of lentiviral vectors in
293T cells.
pMD.G (VSV-G envelope), pCMVΔR-8.92 (Packaging construct), pRSV-Rev (Rev protein) and SIN-W-PGK
(transfer vector). CMV: cytomegalovirus promoter. GAG: structural precursor protein producing the matrix,
capsid and nucleocapsid. LTR: long-terminal repeat. PGK: mouse phosphoglycerate kinase 1 promoter. RSV:
Rous sarcoma virus promoter. RRE: Rev-responsive element. SA: splice acceptor. SD: splice donor. SIN: self-
inactivating (deletion of the U3 region of the 3’ LTR). POL: sequence conding for the reverse transcriptase and
integrase. PolyA+: polyadenylation signal. PRO: protease. ψ: packaging signal. VSVG: vesicular stomatits virus
G glycoprotein. WPRE: post-transcriptional regulatory element from the woodchuk hepatitis virus.
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3.3.2. In vivo experiments
YAC72 mice (mouse line FVB-TgN (353G6-72) 2511, YAC72) and wild-type FVB/N (Iffa-
Credo, France) mice (Hodgson et al., 1999) were used in these studies. The animals were
housed in a controlled temperature room that was maintained on a 12 hr light/dark cycle.
Food and water were available ad libitum. The animals injected with lentiviral vectors were
maintained in ventilated cabinets in biosafety level 2 laboratories. The experiments were
carried out in accordance with the European Community Council directive (86/609/EEC) for
care and use of laboratory animals.
3.3.3. Injection of the lentiviruses
The concentrated viral stocks were defrosted and re-suspended by repeated pipetting. CNTF
or LacZ-expressing lentiviral vectors were stereotaxically injected in the left (1µl) and right
(1µl) striatum of 4 months old pentobarbital anesthetized (75 mg/kg, i.p.) FVB/N and YAC72
mice using a Hamilton syringe with a 33 gauge blunt tip needle (Hamilton, Reno, NV, USA).
The stereotaxic coordinates for the injection were: 0.4 mm rostral to bregma; 1.8 mm lateral
to midline (LM); 3.5 mm ventral from the dural surface. The suspension was injected at 0.2
µl/min by means of an automatic injector (Stoelting Co., IL, USA) and the needle was left in
place for 5 min. The skin was closed using a 6-0 Vicryl® suture (Ethicon, Johnson and
Johnson, Brussels).
3.3.4. Behavioral Analysis
Mice were placed in a monitoring box (10 x 10 x 30 cm) (Digiscan Animal Activity Monitor,
AccuScan Instruments, OH, USA) and their activity recorded for 2 hr. Infra-red beam breaks
were converted into total distance traveled. The activity was tested every other week at a fixed
time corresponding to the dark phase period for the animals (inverted light cycle). The test
was performed during the entire experimental period.
3.3.5. CNTF mesurements
The animals were sacrificed, perfused in ice-cold BPS containing 0.02% ascorbic acid
(Sigma, MO, USA) and 5’000U of heparin (Liquemin, Roche Pharma, Reinach, Switzerland).
70
The in vivo synthesis of CNTF was determined from 2 mm long striatal punches taken around
the injection sites and from corresponding non-injected hemispheres. The samples were
rapidly frozen on dry ice and kept at -80°C until processing. The samples were sonicated in
500 µl PBS, containing a cocktail of protease inhibitors (pronase, thermolysin, chymotrypsin,
trypsin, papain; Roche Pharma, Reinach, Switzerland). Quantitative analysis of the production
of CNTF was performed by an ELISA assay according to the supplier’s manual (R&D system
Abington, UK).
3.3.6. Histological processing
The mice were sacrificed by a sodium pentobarbital overdose and then transcardially perfused
with a 4% paraformaldehyde containing saline solution. The brains were removed, weighed
and one hemisphere was post-fixed in 4% paraformaldehyde for approximately 24 hr and
cryoprotected in 25 % sucrose / 0.1M phosphate buffer (PBS) for 48 hr. These samples were
frozen in dry ice and coronal sections were cut on a sliding microtome cryostat (Cryocut
1800, Leica Microsystems, Nußloch, Germany) at a temperature of -20˚C and a thickness of
20 µm. Slices throughout the entire striatum were collected and stored in 48 well trays
(Costar, Cambridge, MA, USA) as free floating sections in PBS containing 0.12 µM sodium
azide. The trays were stored at 4˚C until immunohistochemical processing.
The second brain hemisphere was post-fixed in 0.15% glutaraldehyde in 0.1M PBS pH7.2.
Fifty micrometers sections were cut with a Leica Ultracut ultramicrotome and cresyl violet
stained to assess the appearance of dark cells. Sections were put for 2 min in sodium acetate
solution containing 0.5% cresyl violet (Sigma, MO, USA) and than rinsed in the acetate
solution. The sections were dehydrated in ethanol, passed in toluene and coverslipped with
Merckoglas®.
3.3.7. Imunohistochemical analysis
Enzymatic staining for nicotinamide adenine dinucleotide phosphate diaphorase (NADPH-d)
was performed as previously described (Ellison et al., 1987). For immunohistochemical
stainings, endogenous peroxidase activity was quenched with 0.1% diphenylhydrazine/PBS
(37°C for 30 min) and washed 3 times in PBS. Free floating sections were incubated
overnight in 5% Normal Goat Serum (NGS, Dako Diagnostics, Untermüli, Switzerland)/0.1M
phosphate buffered saline at 4°C, followed by an overnight reaction in a PBS/1%NGS
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solution, with the respective antibodies: DARPP-32 (1:5000, Chemicon, CA, USA), LacZ
(1:500, 5 Prime 3 Prime Inc., USA), GFAP (1:300, Clontech, CA, USA) and neuronal nuclei
(NeuN, 1:400, Chemicon, CA, USA). After 3 washes, the sections were incubated with the
corresponding biotinylated secondary antibodies (1:200, Vector laboratories, CA, USA) for 2
hr at room temperature. Bound antibodies were visualized with the ABC system (Vectastain
ABC Kit, Vector Laboratories) and 3,3’ diaminobenzidine as chromogen (DAB Metal
Concentrate, Pierce, IL, USA). The sections were dehydrated in ethanol, passed in toluene
and coverslipped with Merckoglas®. Secondary antibodies coupled to fluorescent
chromophores (Jackson ImmunoResearch Laboratories, West Grove, USA) were used for
LacZ (FITC-Goat Anti rabbit, 1:200). The sections were mounted on glass slides with
Fluorsave™ Reagent (Calbiochem-Novabiochem Corporation, CA, USA).
3.3.8. Quantification of NADPH-d and LacZ-positive cells
Counts were performed on 9 NADPH-d stained sections per animal (240 µm apart) and 18
LacZ-stained sections per animal (120 µm apart). The number of cells were extrapolated with
the Abercrombie’s equation with the following parameters: section thickness, 20 microns;
nuclear diameter, 5 microns; section selection, 1/8 for LacZ and 1/16 for NADPH-d.
3.3.9. Stereological analysis
The quantification of the DARPP-32 and NeuN cells was performed on 18 sections (120 µm
apart) per animal with an Olympus microscope and analyzed with the stereological software
C.A.S.T. Grid (The International Stereology Center Olympus Albertslund, Danmark) using
the optical dissector method. Briefly, the striatum area (ROI) was defined at low
magnification (1.25x) and striatum volume was integrated using the method of Cavalieri.
Neuronal count was performed at a magnification of 100x on grid of 500 µm x 300 µm and
the optical dissector was set at 10 µm. An average of 20 grids were used per section analyzed.
3.3.10. Data analysis
Data are expressed as mean ± SEM and evaluated for analysis of variance (ANOVA)
followed by a Scheffe’s PLSD post-hoc test (JMP 3.0, SAS Institute Inc., USA). The
significance level was set at p<0.05.
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3.4.  RESULTS
3.4.1. Stable and long-term transgene expression in the striatum
Figure 24 shows the lentiviral vectors used for the assessment of long-term in vivo expression
of CNTF in wild type and YAC72 mice. Striatal punches, collected up to a year post-lentiviral
injection, were processed for ELISA. Average values of approximately 500 pg CNTF/punch
were measured, whereas no CNTF was detected in control animals or in animals injected with
LacZ lentiviral vectors (Figure 25). CNTF expression was sustained and no significant
differences were observed over time, or between wild type and YAC72 mice (Figure 25).
These results further demonstrate that lentiviral vectors lead to long-term and sustained
transgene expression in the CNS (Déglon et al., 2000).
Interestingly, the local and continuous delivery of CNTF in the striatum of these mice was not
associated with a loss in body weight (26± 1 g WT-LacZ vs 26±4 g WT-CNTF at 13 months),
a side effect previously observed with systemic administration of this neurotrophic factor
(Penn et al., 1997).
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Figure 25:Sustained lentiviral-mediated expression of CNTF in the striatum of mice.
Striatal punches from wild-type and YAC72 transgenic mice were taken 2 to 54 weeks post-injection of CNTF-
or LacZ-expressing lentiviral vectors and processed for ELISA assay. Values below the detection level (20 pg)
were measured on non-injected hemispheres (ctrl) or LacZ-infected striata (LacZ). Values are expressed as mean
± SEM.
3.4.2. CNTF delivery decreases the behavioral deficit of YAC72 mice
The appearance of behavioral abnormalities, in particular hyperactivity, was assessed by
measuring locomotor activity with the open field test (Figure 26). A progressive spontaneous
hyperactivity, starting at 5 months of age, was observed in the YAC72-LacZ mice (Figure
26). Although a large inter- and intra-individual variability was observed, the total distance
traveled was higher in YAC72-LacZ mice than in wild type animals. At 7 and 8 months a
significant hyperactivity was recorded in the YAC72-LacZ mice compared to the WT group.
Importantly, CNTF-treated mice displayed lower spontaneous activities compared to YAC72-
LacZ mice and statistically significant differences were observed at 5 (p= 0.04) and 8 months
(p= 0.03) (Figure 24). Performances in other behavioral tests such as foot-clasping and
rotarod did not differ significantly between groups (data not shown).
Figure 26: Decreased hyperactivity in CNTF-treated YAC72 mice.
Values represent the mean of total distance in meters traveled in the activity box during 2 hr. The general activity
of WT/LacZ and WT/CNTF mice were similar and have been plotted together in the graph. LacZ-injected
transgenic mice (n=6) displayed an increased activity starting at 5 months of age, whereas YAC/CNTF mice
(n=7) displayed a normal activity. Significant differences between the YAC/LacZ and the YAC/CNTF was
found at 5 and 8 months (* p= 0.04, ** p=0.03). Values are expressed as mean ± SEM.
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3.4.3. Effect of long-tern CNTF delivery
a) Brain weight and LacZ expression
Mouse brains were weighed to assess for global brain weight loss. At 13 months of age, no
significant differences were observed between wild type and YAC72 mice (WT-LacZ (n=3):
0.610 ± 0.058g, WT-CNTF (n=3): 0.581 ± 0.038g, YAC72-LacZ (n=6): 0.576 ± 0.006g,
YAC72-CNTF (n=6): 0.599± 0.013g).
In wild type mice, 35’629 ± 6’662 LacZ-infected cells covering a large area of the striatum
were detected 9 months post injection (Figure 27A). These results correspond to the typical
infected area observed 2 weeks post-infection (data not shown). Interestingly, a smaller
number of LacZ-positive cells (12’709 ± 464) was observed in YAC72-LacZ injected animals
probably due to the loss of infected cells (Figure 27B). Large nuclear structures with intense
LacZ staining (of unknown significance) were observed in the striatum of YAC72-LacZ mice
but were not seen in wild type-LacZ animals mice (Figure 27A). These differences in the
observed pattern of LacZ expression may reflect the ongoing neurodegenerative process
occurring in the YAC72 mice.
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Figure 27: Loss of LacZ-positive cells in the striatum of YAC72 mice at 9 month post-injection.
(A) Photomicrograph of LacZ-infected cells in the striatum of a wild type and YAC72 mice. (B) Histogram
showing the number of LacZ-infected cells in wild type (n=2) and YAC72 (n=6) mice. Values are expressed as
mean ± SEM
b) Dark cells
Cresyl violet stained sections were used to reveal the presence of striatal dark cells and
assesses the effect of CNTF on the incidence of these cells. Dark hyperchromatic neurons
were visible in YAC72-LacZ mice (Figure 28A), whereas no sign of these cells was found in
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WT-LacZ and WT-CNTF animals. The intra-striatal administration of CNTF significantly
reduced the number of dark cells: in YAC72-CNTF mice (60 ±16) compared to YAC72-LacZ
mice (129±12; p<0.001) (Figure 28 Aand B). This effect was not limited to the injection site
but was observed throughout the striatum (data not shown).
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Figure 28: Significant reduction of cresyl violet-stained dark cells in YAC72-CNTF mice.
A) Photomicrographs of dark cells in the striatum of YAC72 mice injected with a LacZ- or CNTF-expressing
lentivirus. Arrow shows some hyperchromatic and shrunken cells. (B) Histogram showing the total number of
degenerating cells in the striatum of YAC72-CNTF (n=7) and YAC72-LacZ (n=6) (*p<0.001). Values are
expressed as mean ± SEM.
c) DARPP-32 and NeuN immunoreactivity
To further assess the effect of CNTF, stereological counts of DARPP-32 stained sections were
performed. This marker of the striatal GABAergic spiny neurons (Ouimet et al., 1998) is
decreased in several mouse models of HD (Bibb et al., 2000; Luthi-Carter et al., 2000; van
Dellen et al., 2000). Interestingly, the long-term expression of CNTF in WT mice led to a
decrease in DARPP-32 labeling as shown in Figure 6A. The neuritic staining and the number
of DARPP-32 positive neurons were reduced (1.10 x 106 ± 0.15) compared with WT-LacZ
animals (1.44 x 106 ± 0.15; p = 0.13) (Figure 29B). Unfortunately, this result precludes
drawing any conclusions from the YAC72 mice, on any potential protective effect of CNTF
on medium spiny neurons (YAC72-LacZ: 1.20 x 106 ± 0.07; YAC72-CNTF: 1.15 x 106 ±
0.11). To further investigate the pathology of 13 months old YAC72 mice and the effect of
CNTF administration, striatal sections were stained with the neuronal marker NeuN. No
significant change in the staining and number of NeuN-positive cells was observed between
WT-LacZ (1.52 x 106 ± 0.06) and YAC72-LacZ mice (1.42 x 106 ± 0.10; p =0.2) whereas a
reduction in the number of NeuN-positive neurons was observed in the CNTF-treated mice
(WT-CNTF: 1.35 x 106 ± 0.07; YAC72-CNTF: 1.04 x 106 ± 0.07; p=0.01) (Figure 30A).
Finally, immunohistochemical analysis of NADPH-d neurons, which are spared in HD
patients, failed to reveal any alterations in the brain of WT and YAC72 mice treated or not
with CNTF (data not shown).
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Figure 29: Stereological counts of DARPP-32 positive neurons.
(A) DARPP-32-stained striatal sections from WT-LacZ, WT-CNTF, YAC72-LacZ and YAC72-CNTF. (B)
Quantification of the total number of the DARPP-32-positive cells in the striatum WT-LacZ (n=3), WT-CNTF
(n=3), YAC72-LacZ (n=6) and YAC72-CNTF (n=7). Values are expressed as mean ± SEM.
d) GFAP staining
Previous in vitro and in vivo studies have shown that CNTF induces astrocyte differentiation
(Kahn et al., 1995;Mayer et al., 1994;Winter et al., 1995). We have therefore performed a
glial fibrillary acidic protein (GFAP) immunostaining to reveal the presence of activated
astrocytes (Figure 30B). Both WT-CNTF and YAC72-YAC72-CNTF-injected animals
showed a substantial GFAP immunoreactivity (Figure 307), whereas only few GFAP-positive
astrocytes were visible in WT-LacZ- and YAC72-LacZ-injected mice (Figure 30).
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Figure 30: Analysis of NeuN stained striatal sections.
(A) NeuN stained striatal sections from WT-LacZ, WT-CNTF, YAC72-LacZ and YAC72-CNTF. (B) Evaluation
of the astrocytic response in WT and YAC72 mice.
Photomicrographs showing GFAP-stained striatal sections in WT-LacZ, WT-CNTF, YAC72-LacZ and YAC72-
CNTF injected animals. The administration of CNTF for 9 months leads to a significant increase in GFAP
immunoreactivity. In YAC72-lacZ mice the staining did not differ from WT-LacZ animals.
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3.5. DISCUSSION
In the present study, we assessed the effect of local and long-term lentiviral-mediated CNTF
expression in the striatum of wild-type and HD transgenic mice. Lentiviral vectors led to
robust transgene expression up to 9 months post-injection in the striatum of mice (Déglon et
al., 2000) and lentiviral-mediated CNTF delivery was shown to protect striatal neurons in a
drug-induced rat model of HD (de Almeida et al., 2001). Lentiviruses expressing the LacZ
reporter gene or human CNTF gene were therefore injected bilaterally in 4 months old wild-
type and YAC72 mice. Nine months post-injection, approximately 35’000 LacZ-infected cells
were counted in wild type mice, whereas a reduction in the number of β-galactosidase-
positive cells was observed in 5 out of the 6 HD transgenic mice. The loss of LacZ expression
may result from the ongoing pathological process occurring in YAC72 mice and suggests that
this reporter gene could be used as a surrogate marker to follow the appearance of HD
pathology in animal models lacking severe neurodegeneration. Whether this loss of LacZ
staining is due to an aberrant transcriptional regulation of the reporter gene, as reported in
various experimental paradigms of HD, still needs to be investigated . The cell bodies of some
spared LacZ-positive neurons appear larger with an intense staining. This phenotype is
reminiscent of the results published by Bence and co-authors. They showed that cells co-
expressing a mutated huntingtin fragment and a destabilized green fluorescent protein (GFP)
have a 4-fold increase in GFP fluorescence compared to controls and that this phenomenon
was due to an impairment of the ubiquitin-proteasome pathway (Bence et al., 2001).
Interestingly, no significant differences in CNTF expression were observed over time or
between wild type and YAC72 mice. This suggests that CNTF expression, contrary to LacZ,
is not affected by mutated huntingtin or that CNTF is altering the ongoing pathology.
During the time-course examined in our experiments, the phenotype of YAC72 transgenic
mice appears to correspond to early stages of the disease, with hyperactivity and neuronal
dysfunction associated with the appearance of dark cells. While nuclear huntingtin staining
increases around 12 months of age very few huntingtin inclusions are identified (Hodgson et
al., 1999). This experimental paradigm was used to assess the impact of a local and
continuous expression of approximately 0.5 ng human CNTF in the striatum. Wild- type
FVB/N littermates were used as control. The development of hyperactivity on open-field
testing was the first parameter examined to assess the disease progression and the impact of
CNTF expression. Large inter- and intra-individual variability of spontaneous explorative
behavior was observed, but significant differences were recorded between wild-type and
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transgenic mice at 5 and 8 months. This heterogeneity and the early stage of the pathology in
YAC72 mice characterized by subtle changes, limits the number of validated outcome
measures, which can reliably be used to monitor the effects of potential therapeutic
candidates. Nuclear inclusions are, for example, very rare in these animals and can not be
used as parameter. Recently a new YAC128 transgenic mouse model of HD has been
developed which has increased levels of transgene expression and an accelerated
neurodegenerative phenotype that is more adequate for therapeutic trials (Slow et al., 2003).
Scattered atrophic neurons with condensed chromatin and a “dark” cytoplasm are present in
affected areas of HD brains (Vonsattel and DiFiglia, 1998). In 17 week-old R6/2 transgenic
mice, degenerating neurons surrounded by neurons with normal appearance were detected in
different brain regions. These dying neurons have a higher affinity for toluidine blue and
exhibit nuclear inclusions and ruffling of the plasma membrane (Turmaine et al., 2000). Dark
neurons were also observed in 5-7 months old R6/1 mice (Iannicola et al., 2000) and in 8-12
months old YAC72 mice (Hodgson et al., 1999). In our study, hyperchromatic and shrunken
neurons were visible in YAC72-LacZ mice and CNTF expression significantly decreases the
number of dark neurons. Whether these dark cells represent a degenerating subpopulation of
neurons is, however, unclear.
Mutant huntingtin expression is associated with regional and temporal alterations in gene
expression (Sugars and Rubinsztein, 2003). Changes in the expression of transcription factors,
neuronal markers, genes implicated in cellular metabolism or neurotransmitter receptors
should, not only, provide important information related to polyQ-mediated neurodegeneration
but also quantitative tools for the evaluation of therapeutic strategies. Histological studies on
R6/2 animals has, for example, revealed a reduction in DARPP-32 and other dopamine-
regulated proteins expressed in medium spiny neurons at 4 to 8 weeks (Bibb et al., 2000; van
Dellen et al., 2000). DARPP-32 is a pivotal regulator of dopamine receptor signaling in the
striatum and is therefore considered as a good marker of the pathology occurring in
presymptomatic mice or early stage of the disease. Interestingly, CNTF expression induced a
drastic down-regulation of DARPP-32 in wild-type mice 9 months post-lentiviral injection.
This effect has not been observed when the same CNTF-expressing lentiviral vector was
injected for 5 to 12 weeks in QA-lesioned rats (de Almeida et al. 2001; unpublished data) or
when CNTF was delivered in 3-NP lesioned primates by encapsulated genetically engineered
BHK cells (Mittoux et al., 2000). How the long-term striatal expression of CNTF leads to a
decrease in DARPP-32 immunoreactivity, and how this change might affect striatal function
still needs to be established. The continuous delivery of nanograms of CNTF was previously
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shown to drastically decrease the extent of striatal damages in drug-induced models of HD
(Emerich et al., 1996; Emerich et al., 1997a; Mittoux et al., 2000; de Almeida et al., 2001).
Differences in the pathological processes between drug-induced and genetic models of HD
may lead a differential effect of CNTF. The mode of action of this cytokine is still poorly
understood and various intracellular pathways might be activated in various animal models of
HD. The binding of the CNTF to the gp130/LIFRβ/CNTFRα receptor complex has been
shown to activate the Jack/STAT and PI3K/Akt signaling pathways (Alonzi et al., 2001).
CNTF, in particular, induces the phosphorylation and nuclear translocation of STA3, a protein
inducing the transcription of Bcl-2 and Bcl-xL genes (Catlett-Falcone et al., 1999; Karni et
al., 1999) and regulating the activity of several transcription factors such as Forkhead 1,
CREB and NF-kB (Du and Montminy, 1998; Brunet et al., 1999; Kane et al., 1999; Ozes et
al., 1999). Long-term expression of CNTF may affect striatal functions either directly or
indirectly. It is well established that CNTF induces a phenotypic alteration of astrocytes in
vivo (Winter et al., 1995; Kahn et al., 1997; Lisovoski et al., 1997; Levison et al., 1998;
Gomes et al., 1999). Consistent with this, we observed an up-regulation of the astrocytic
marker GFAP in the striatum of Lenti-CNTF injected mice. This astrocytic response covers
the entire striatum and is probably due to diffusion of CNTF throughout this structure.
Recently, Albrecht and co-authors showed that CNTF treatment lead to an activation of spinal
cord astrocytes, the production of various growth factors and to an increased survival of CNS
neurons compared to untreated astrocytes (Albrecht et al., 2002). They propose that cytokine-
activated astrocytes have an enhanced buffering capacity leading to decreased levels of
harmful energy metabolites, which may indirectly protect neurons. This same indirect CNTF-
mediated mechanism could be activated in the striatum and therefore protect neurons
undergoing degeneration. Chronic impairments of mitochondrial energy metabolism are
indeed thought to be involved in neurodegenerative diseases, including HD.
Studies are needed to further assess CNTF’s effect on striatal functions and its impact on HD
pathology corresponding not only to an early stage of the disease but also to grade 2-4
pathologies.
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4. BDNF DELIVERY IN GENETIC MODELS OF HUNTINGTON’S
DISEASE
4.1. ABSTRACT
Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family, is necessary
for normal striatal neuron function and for long-term survival of MSNs. The possible
involvement of this factor in HD pathology is supported by recent data showing that mutant
huntingtin interferes with BDNF expression in the cortex and impairs BDNF vesicular
transport. The loss of trophic support may therefore contribute to the pathogenesis. Beside its
survival property for MSNs, BDNF was also shown to be neuroprotective in a toxin-induced
striatal lesion model of HD, as well as in primary striatal neurons expressing mutant htt
fragments. Therefore, BDNF might prevent striatal degeneration in Huntington’s disease. In
the present study, we have further assessed the protective effect of BDNF in two genetic
models of HD. BDNF was delivered in the striatum of YAC128 mice and in a lentiviral-based
rat model of HD. The expression of BDNF was achieved without side effects, but motor
deficits, down-regulation of DARPP-32 and formation of htt aggregates were not found to be
prevented in these experimental paradigms.
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4.2. INTRODUCTION
Brain-derived neurotrophic factor (BDNF) is a potent survival factor for striatal neurons
(Ventimiglia et al., 1995) and it induces the differentiation of striatal GABAergic, calbindin-
and DARPP-32-positive cells (Mizuno et al., 1994; Nakao et al., 1995). BDNF is synthesized
in the cortex and anterogradely transported to the striatum, where it is stored in dense-core
vesicles before its release (Sobreviela et al., 1996). BDNF null-mutant mice present a
reduction of striatal projecting neurons, but such animals do not survive long enough to
evaluate the effects of a chronic depletion of this trophic factor in striatal neurons. (Jones et
al., 1994; Ivkovic et al., 1997). Recently, the crossing of transgenic floxed BDNF mice with
Emx1IREScrel+ has generated viable mice that lack cortical BDNF. Eighteen-month-old
animals display a loss of medium spiny neurons, thus further illustrating the importance of
this trophic factor for GABAergic neurons in adults (Baquet et al., 2004). Interestingly, the
mice present several analogies with R6/2 transgenic mice, notably the forelimb clasping
behavior and a reduction of CNS volume. Evidence that BDNF influences HD pathology was
further obtained by cross-mating bdnf +/-  mice with R6/1 mice; an earlier onset of motor
deficits and a lack of DARPP-32 expression in the striatum were observed in the double-
transgenic mice (Canals et al., 2004).
In addition, a depletion of striatal BDNF was reported in the brain of HD patients and in
transgenic mice (Zuccato et al., 2001). Two mechanisms may contribute to this trophic
decrease, since both the cortical BDNF transcription and the vesicular transport of BDNF are
impaired by mutant htt (Zuccato et al., 2003; Gauthier et al., 2004). Therefore restoring
striatal BDNF could represent a therapeutic approach to prevent medium spiny neuron
degeneration. Interestingly, BDNF was proposed as therapy for HD before it was linked to the
disease. BDNF was shown to protect GABAergic neurons in drug-induced models of HD
(Alberch et al., 2004), as well as in rat striatal cultures expressing a mutant huntingtin
fragment (Saudou et al., 1998) (see chapter 2.4.7). In addition to its potential neuroprotective
effect, BDNF might induce neurogenesis in the adult rodent striatum (Benraiss et al., 2001;
Pencea et al., 2001), which could be especially interesting for a chronic neurodegenerative
disease such as HD.
Motivated by these data, we have further tested the protective effect of BDNF in two genetic
models of HD which are characterized by mild, respectively severe pathologies. We have
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used the YAC128 mice (Slow et al., 2003), which express the full-length huntingtin with 128
CAG repeats. The level of expression of human htt is approximately five times higher than
that of the endogenous protein and the polyQ expansion increases in these transgenic mice
from 72 to 128 glutamines. As a result, these mice have a more severe phenotype than
YAC72 mice (Hodgson et al., 1999). They are behaviorally impaired as recorded by the
accelerated rotarod and activity box; at one year of age they show a 20% striatal atrophy and
10% reduction of striatal neuronal sections. To try to reverse this phenotype, we have
bilaterally injected Lv-BDNF in the striatum of these transgenic mice. The neuronal
pathology was evaluated at 18 months.
The second experimental paradigm was the lentiviral-based rat model expressing the first 853
amino acids with 82 CAG repeats under the control of a tetracycline promoter (Régulier et al.
2003). We have chosen this experimental paradigm to evaluate the potential effect of BDNF
in severely lesioned animals. At three months post-injection, the expression of mutant htt
fragments induces a severe lesion, which is characterized by neuronal loss, striatal shrinkage
and ventricle enlargement.
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4.3. MATERIAL AND METHODS
4.3.1. Lentiviral vector production
The cDNAs encoding enhanced GFP, LacZ, human CNTF (Clonetech, Palo Alto; USA),
human NGF (human pre-proNGF domain [nucleotides 170-532, Genbank X52599] fused to
human BDNF [nucleotides 681-1040, Genbank X60201] to obtain a chimera BDNF (Figure
31)) and the first 853 amino acids of human huntingtin containing 19 or 82 CAG repeats,
controlled by the PGK or TRE promoter, and PGK-tTA1 were cloned in the SIN-W transfer
vector as previously described in chapter 2.3.2.
4.3.2. Cell cultures
E16 rat primary striatal cultures were dissected, cultured and infected with Lv-BDNF or Lv-
GFP as previously described in chapter 2.3.1. The concentrations of BDNF were determined
by ELISA (R & D, Abingdon, UK) on media samples collected at 2 weeks and stored at -
20°C until use. Samples were processed according to the manufacturer’s instructions. The
detection limit was 20 pg/ml for BDNF.
293T cells were transfected with wild-type BDNF or chimeric preproNGF-BDNF. Two days
later media were replaced and collected after two hours, then stored at –20°C until use.
4.3.3. Western blot analysis
Cellular lysates were harvested in lysis buffer (125mM Tris·HCl/0.5% SDS/1% Nonidet P-40)
containing protease inhibitors (Roche Pharma, Basel, Switzerland). Protein concentrations of
cytoplasmic fractions were determined with the BCA protein assay kit (Pierce Biotechnology
Inc, Rockford, USA). Equal amounts of protein (50 µg) or equal amounts of medium (25µl)
were loaded on 10% or 15% sodium dodecyl sulfate (SDS) polyacrylamide gel and
transferred onto nitrocellulose membrane (Schleicher & Schuell Bioscience GmbH,
Dassel/Relliehausen, Germany). Immunoblotting was performed by using a rabbit polyclonal
antibody BDNF; 1:10’000; Santa Cruz, USA or mouse monoclonal antibody DARPP-32;
1:10’000; Chemicon International Inc., Temecula, USA, followed by goat anti-mouse or anti-
rabbit horseradish peroxydase (HRP) antibody (1:2’000; DakoCytomation AG, Zug,
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Switzerland). Visualization of the proteins was achieved with an ECL and chemiluminescence
detection kit (Amersham Biosciences Europe GmbH, Freiburg, Germany) in a Multimage
Light Cabinet (Alpha Innotech Corporation, San Leandro, USA).
4.3.4. Animals
The animals were housed in a controlled-temperature room that was maintained on a 12 h
light/dark cycle. Food and water were available ad libitum. The experiments were carried out
in accordance with the European Community Council directive (86/609/EEC) for care and use
of laboratory animals.
4.3.5. Experiment 1: BDNF assay in YAC128 mice
YAC128 mice and wild-type FVB/N (Iffa-Credo, France) mice (Slow et al., 2003) were used
in these studies. Stereotaxic injections were performed as previously described in chapter
3.3.3. Nine-month-old mice were bilaterally injected in the striatum with 2 µl of lentiviral
vectors at p24 of 100’000 ng/ml: YAC128 (N=8) and WT (N=10) with SIN-PGK-BDNF at a
p24 of 100 000 ng/ml and control animals YAC128 (N=8) and WT (N=10) were injected with
SIN-PGK-GFP at a p24 of 100’000 ng/ml. The animals were sacrificed at the age of 18
months. Additional YAC128 (N=3) and WT (N=8) mice were injected with lenti-BDNF in
one hemisphere and lenti-GFP in the other hemisphere and sacrificed after 2 weeks to
determine BDNF and GFP expression.
4.3.6. Behavioral tests
a) Spontaneous activity
Spontaneous activity was recorded during 30 minutes with the activity boxes. For details see
chapter 3.3.4.
b) Accelerated rotarod
Mice were placed on the rotarod and the speed was progressively increased from 0 to 45 rpm
over a period of 120 s. Mice were trained for 3 days with three trials per day. Following this
training period, the mice were tested for three consecutive trials in one day, with at least
30min rest between trials and the best score was recorded.
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4.3.7. Experiment 2: BDNF assay on the lentiviral rat model
Adult female Wistar rats (Iffa Credo / Charles River, Les Oncins, France) weighing 180-200g
were used. The animals were maintained in the “off” state 3 weeks after the first lentivirus
injection with the addition of 200 mg/l doxycycline (Dox, Sigma Chemical CO, Saint Louis,
USA) in drinking water containing 40g/l sucrose (corresponding approximately to 20 mg
Dox/rat/day) and put “on” after the second injection of Lv-BDNF or Lv-GFP.
Concentrated viral stocks were thawed and resuspended by repeated pipetting. Lentiviral-
expressing vectors were stereotaxically injected into the striatum of ketamine (75 mg/kg, i.p.)
and xylazine (10 mg/kg, i.p.) anesthetized animals using a Hamilton syringe with a 34-gauge
blunt-tip needle (Hamilton, Reno, USA). A 1:1 ratio in particle contents was used for
lentiviral co-injection with 100’000 ng of p24/ml of PGK-tTA1 and 100’000 ng/ml of p24 of
TRE-853-82Q. The viral suspensions (4µl) were injected at 0.2µl/min by means of an
automatic injector (Stoelting Co., Wood Dale, USA) and the needle was left in place for an
additional 5 min. The stereotaxic coordinates were: 0.5 mm rostral to bregma; 2 and 3 mm
lateral to midline and 5 mm from the skull surface. The skin was closed using a 6-0 Prolene®
suture (Ethicon, Johnson and Johnson, Brussels, Belgium). At three weeks bilateral lentiviral
injection was performed with lenti-GFP and lenti-BDNF (N=8); each Lv was injected at
100’000 ng of p24/ml. The stereotaxic coordinates were: 0.5 mm rostral to bregma; 2.5 mm
lateral to midline and 5 mm from the skull surface. In addition rats injected only with Lv-
GFP, Lv-BDNF or mixed Lv-tTA1 and Lv- TRE-853/82Q were used as control (N=4). Three
months later, the rats were sacrificed.
4.3.8. Histological processing
Mice or rats were given a sodium pentobarbital overdose and transcardially perfused with
saline and 4% paraformaldehyde. The brains were removed and postfixed in 4%
paraformaldehyde for 24 h and finally cryoprotected in 25% sucrose /0.1 M phosphate buffer
for 48 h. The brains were frozen in dry ice and 25 µm coronal sections were cut on a sliding
microtome cryostat (Cryocut 1800, Leica Microsystems AG, Glattbrugg, Switzerland) at
-20˚C. Slices throughout the entire striatum were collected and stored in 48 well trays (Costar,
Cambridge, USA) as free floating sections in PBS supplemented with 0.12 µM sodium azide.
The trays were stored at 4˚C until immunohistochemical processing. Striatal sections from
injected rats were processed by immunochemistry for DARPP-32 as previously described in
chapter 2.3.3. The sections were mounted, dehydrated by passing twice through ethanol and
toluene and coverslipped with Merckoglas® (EM Science, Gibbstown, USA).
Image Analysis
The htt lesions were analyzed by directly measuring the area of the lesion in DARPP-32-
stained sections (200µm between sections) by microscope acquisition at a magnification of
1,5x (software: Analyses, Olympus). Sections throughout the entire striatum were analyzed.
Data are expressed as the volume of the lesion in mm3. Ventricle size was analyzed on cresyl
violet stained sections (200µm between sections) with the same software. Data are expressed
as the volume in mm3.
4.3.9. Data analysis
Quantifications are expressed as mean ± SEM. Statistical analysis was performed by one-way
analysis of variance (ANOVA) followed by a Newman-Keuls post-hoc test (Statistica 5.1,
Statsoft Inc, USA). The significance level was set at p<0.05.
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4.4. RESULTS
4.4.1. Lv-BDNF is released and is bioactive in striatal neurons
We have constructed a preproNFG-BDNF vector by fusing the signal peptide of the
preproNGF to mature BDNF. This chimeric BDNF should be efficiently processed trough the
constitutive pathway and the mature BDNF released in the extracellular space (Haubensak et
al., 1998; Mowla et al., 1999) (Figure 31).
Figure 31: Strategy to increase BDNF secretion
The prepro-domain of BDNF was deleted and BDNF cDNA fused to the prepro domain of NGF to produce the
chimeric preproNGF-BDNF protein.
To test if the chimeric preproNGF-BDNF was properly processed and released, we transiently
transfected 293T cells with the plasmids coding for wild type or chimeric BDNF and analyzed
the samples by Western blot (Figure 32A). The polyclonal antibody recognized both the
human recombinant and the chimeric BDNF, and a band with the expected molecular weight
of 15 kDa was observed. In contrast, wild type human BDNF was not efficiently secreted.
This probably reflects the poor processing of prepro-BDNF and the absence of regulated
BDNF secretion in 293T cells. This confirms previous results from our laboratory showing
that wild type BDNF is inefficiently produced in different mammalian cells. Based on the
titration with the recombinant protein, we have estimated that the amount of BDNF released
in the supernatant of 293T cells is between 1-5 ng/ml.
The lentiviral vector coding for the chimeric BDNF was produced and further validated in rat
primary striatal cultures. Western blot analysis of media collected 2 weeks post-infection
showed that the Lv induced production and processing of mature BDNF (Figure 32B).
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Quantitative measurement of BDNF secretion by ELISA showed that 715 +/- 357 pg/ml
(N=4) of the protein are present in the media of infected cells. Measurements of on-infected
or Lv-GFP infected cultures showed concentrations below the detection limit.
Figure 32: Functionality of the chimeric proNGF-BDNFvector
(A) 293T cells were transfected with BDNF, preproNGF-BDNF-plasmids or mock-transfected. The anti-BDNF
antibody recognized a band at 15 kDa in the columns loaded with recombinant protein and in the proNGF-BDNF
column. (B) Supernatant of rat striatal cultures infected with Lv-preproNGF-BDNF was analyzed by Western
blot, showing that BDNF was correctly processed and secreted. (C) Cell fractions of striatal culture infected with
Lv-preproNGF-BDNF or control cultures were lyzed and blotted against antibody DARPP-32. A faint band
corresponding to DARPP-32 was detected in the control cultures, whereas BDNF expression increased the
32kDa signal. An unspecific band at 26 kDa was used to show equal protein loading.
We have also tested the bioactivity of chimeric BDNF in primary striatal cultures. BDNF was
shown to promote striatal GABAergic differentiation in vitro, notably by enhancing DARPP-
32 expression (Ivkovic et al., 1997). At two weeks post-infection, an up-regulation of
DARPP-32 expression was observed in Lv-BDNF infected cells, compared to non-treated
control cultures (Figure 32C).
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4.4.2. Lentiviral-mediated delivery of BDNF in the mouse striatum
Finally, the functionality of the BDNF expression vector was assessed in vivo by the injection
of Lv-BDNF in mouse striatum. Two weeks later, striatum and hippocampus were dissected,
homogenized and the expression of BDNF analyzed by Western Blot. The hippocampus was
used as internal control, because it has a high BDNF expression (Conner et al., 1997). In this
structure, a 15 kDa band corresponding to the recombinant protein was detected, as well as
three higher molecular bands probably representing unprocessed BDNF (Figure 33A). As
expected, BDNF expression level was higher in injected striatum compared to control non-
injected hemispheres (Figure 33B).
Figure 33: In vivo expression of BDNF
(A) Hippocampus from adult mice was dissected lyzed and endogenous BDNF expression analyzed by Western
Blot. A band migrating at the same molecular weight as recombinant BDNF was detected, as well as three higher
bands probably representing unprocessed BDNF. (B) Mouse striata injected with lenti-BDNF or control animals
were dissected 2 weeks post-surgery and analyzed by Western Blot. A stronger BDNF signal is detected in the
injected hemisphere.
4.4.3. Experiment 1: BDNF assay in YAC128 mice
4.4.3.1. Behavior and body weight evolutions
To evaluate the protective effect of BDNF, 9-month-old YAC128 and wild type mice were
bilaterally injected with either lenti-BDNF or lenti-GFP. At thar stage, the animals display
only subtle striatal atrophy with no decrease in neuronal cell body section (Slow et al., 2003).
During the following 9 months, the motor deficits were measured with the accelerated rotarod
and spontaneous activity tests. Statistically significant differences in the rotarod performance
of wild type and YAC128 mice were already observed at 10 months and persisted over
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time. Importantly, the delivery of BDNF did not modify the behavioral deficit of HD
transgenic mice (Figure 34A). Similar results were obtained with the spontaneous activity
test. The Figure 34B showed that wild type animals were more active than YAC128 mice and
that BDNF administration did not influence this hypoactivity (Figure 34B)
Figure 34: Behavioral tests
(A) Accelerated rotarod tests were performed every 3 months. The latency to fall was recorded and showed a
statistically significant decrease in both YAC128 groups compared to wild type groups at each time point
(*p<0.05). In both groups the delivery of BDNF did not affect the behavior performance. (B) Spontaneous
activity was recorded periodically; wild type mice traveled more than YAC128 mice at each time point
(*p<0.05), but the delivery of BDNF did not increase hypoactivity in the transgenic mice.
The decreased latency before falling from the rotarod and the hypoactivity recorded in
transgenic mice were correlated with the progressive increase in body mass of HD transgenic
mice (Figure 35).
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Figure 35: Evolution of the body weight
Body weight of wild type and YAC128 mice was periodically measured. YAC128 weighted more than wild type
with a mean difference of 7g (+ 20%). This difference was maintained until 15 months and was reduced only at
month 18 (p < 0.01 at 9,12,15 months). The groups of BDNF and GFP treated mice were similar and were
therefore not represented in this graph.
4.4.3.2. Brain weight and striatal volume
One-year-old YAC128 mice were shown to display a general brain atrophy and in particular a
15% decrease of striatum volume as compared to wild-type mice (Slow et al., 2003). We have
therefore used these two parameters to further assess the protective effect of BDNF in 18-
month-old YAC128 mice. At this stage DARPP-32 is not downregulated (Figure 36A) and rare
aggregates are present in the striatum of transgenic mice (Figure 36B) as well as in other brain
regions (data not shown).
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Figure 36: DARPP-32 and ubiquitin staining in YAC128 at 18 months
Wild-type and YAC128 mice brain sections were stained against (A) DARP-32 and (B) ubiquitin. No difference
of DARPP-32 staining was observed between the four experimental groups. Few aggregates were observed in
the striatum of YAC128 mice (V).
V
V
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To our surprise, the brain weights and striatal volumes measured on DARPP-32 stained
sections were not significantly different between wild type and YAC128 mice (Figure 37 A-B).
The protective effect of BDNF could therefore not be evaluated in this experiment.
Figure 37: Brain weight and striatal volume at 18 months
(A) Injected YAC128 and wild type mice were sacrificed at 18 months. Histogram shows the brain weights of all
four groups. (B) Striatal volume was analyzed on DARPP-32-stained section (Data are expressed as mean
±SEM)
4.4.4. Experiment 2: BDNF in lentiviral-based rat model of HD
Due to the severity of the pathology in the lentiviral-based model of HD, was chosen as
second experimental paradigm to test the protective effect of BDNF. We have previously
shown that the delivery of lentiviral vectors encoding mutant htt 853-82Q fragment under the
control of a tetracycline-regulated promoter is inducing a striatal pathology, which is
characterized by a reduction of DARPP-32, the proteolytic release of N-terminal htt fragments
and nuclear aggregation at 3 months (Régulier et al., 2002; Régulier et al., 2003). In these
experiments, rats were bilaterally injected with a lentiviral mixture of Lv-PGK-tTA1 and Lv-
TRE-853; dox was added in the drinking water to switch off huntingtin expression. Three
weeks later, dox was removed and one hemisphere was injected with Lv-BDNF and the other
hemisphere with Lv-GFP. In addition, rats expressing only mutant htt, BDNF or GFP were
used as controls.
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Figure 38: Striatal degeneration in rat striata
Three months post-injection of tet-htt 853-82Q, a severe lesion was observed. (A) The pathology is characterized
by a drastic loss of DARPP-32 immunoreactivity, (B) an enlargement of the ventricle due to striatal shrinkage
and a coalescence of the internal capsule of the striatum. (C) Quantification of the lesion volume in treated
(BDNF) and control (GFP) groups shows that BDNF has no significant protective effect (p = 0.2).
As previously reported, mutant htt expression leads to a loss of DARPP-32 immunoreactivity,
3 months post-injection (Figure 38A). In control animals, co-expressing htt853-82Q and GFP
reporter gene, a lesion of 1.56±0.13 mm3 was observed. This lesion volume was slightly
decreased in BDNF-treated animals with a volume of 1.28±0.19 mm3, but it did not reach
statistical significance. No up-regulation of DARPP-32 expression was observed in BDNF-
treated striatum as compared to control hemispheres (data not shown).
In the control group, the HD pathology induced a tissue shrinkage and coalescence of the
internal capsule of the striatum (Figure 38B). This striatal shrinkage induced a ventricle
enlargement, reminiscent of advanced stages of HD in patients. To take into account tissue
contraction, we have quantified the ventricle size and used this as an indirect measurement of
striatal shrinkage. Mutant htt induced a two-fold volume dilatation of the ventricle (Figure 39).
However, the delivery of BDNF did not reduce this enlargement.
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Figure 39: Quantification of the ventricle volume.
Evaluation of ventricle volumes three months post-infection. Mutant htt delivery induced a significant
enlargement of the lateral ventricle volume (p<0.05). The co-expression of BDNF or GFP with mutant htt did
not modify the ventricle dilatation.
Finally, we analyzed whether the expression of BDNF may alter the formation of htt
aggregates. In htt853-82Q injected rats, numerous nuclear and neuritic htt inclusions were
present in the striatum (Figure 40). The expression of BDNF did not modify the formation
and/or the subcellular localization of aggregates.
Figure 40: Huntingtin aggregation is not modified by BDNF
Htt staining (mEm48) at three months htt expression showed no qualitative difference of type or number of
aggregation or number in the 3 different experimental groups.
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4.5. DISCUSSION
Several links have been traced between Huntington’s disease and brain-derived neurotrophic.
First, mutant htt interferes with BDNF transcription and transport, which leads to a striatal
trophic factor depletion that could partially explain the preferential neuronal loss in this brain
region. Second, BDNF is a potent survival factor for striatal neurons in various experimental
paradigms. Recently, the breeding between R6/1 and BDNF+/- mice demonstrated that a
deficit of endogenous BDNF modulates HD pathology. Interestingly, the administration of
exogenous BDNF restores neuronal function in these double-mutant mice (Canals et al.,
2004). BDNF has been reported to protect striatal neurons expressing a mutant htt fragment in
an acute (Saudou et al., 1998) as well as also in a chronic cellular model (see Chapter 2.4.7).
In vivo, the potential of BDNF has been assessed in the quinolinic acid model (Bemelmans et
al., 1999; Kells et al., 2004), but no data are available for the genetic models of HD. The
evaluation of its impact in genetic models of HD is, therefore, essential to establish its clinical
relevance.
In the present study, a lentiviral vector coding for a chimeric human BDNF was injected in
the striatum of adult mice and rats. BDNF is produced as a pre-pro-precursor, which is further
processed until it is eventually released through the regulatory secretory pathway (Mowla et
al., 1999). NGF, another member of the neurotrophin family, is secreted by the regulated
pathway (Mowla et al., 1999), but also by the constitutive pathway (Wu et al., 2004). In a
side-by-side comparison, Wu and collaborators showed that in cortical primary cultures
infected with adenoviral vectors NGF is released 10 times more efficiently than BDNF (Wu et
al., 2004). To increase the secretion of BDNF, we have constructed a fusion protein with the
pre-pro peptide of NGF and the mature BDNF. This chimeric protein was efficiently
processed and secreted in vitro and in vivo and its bioactivity was demonstrated in striatal
cultures.
In our first attempt to establish the neuroprotective effect of BDNF, we delivered this trophic
factor in YAC128 mice. Surprisingly, these mice did not develop major signs of striatal
pathology at 18 months. These results are in contradiction with previously reported data
describing brain atrophy and neuronal dysfunctions at one year (Slow et al. 2003). One
potential hypothesis to explain this discrepancy relates to the housing conditions. It has been
shown that enriched environments have a beneficial impact on R6/2 transgenic mice (Hockly
et al., 2002; Spires et al., 2004). In addition, subtle environmental changes may have drastic
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consequences on the results of behavioral tests (Crabbe et al., 1999). Food dietary could also
be a major disease modifier. Indeed, dietary manipulation has been described to influence
disease progression in HD transgenic mice (Clifford et al., 2002; Duan et al., 2003). Finally, a
recent paper from the Venezuela Research Project shows that environmental factors modulate
the age of onset of Huntington’s disease (Wexler et al., 2004).
Although we did not observe a striatal pathology in 18-month-old YAC128, a progressive
increase in body mass was measured in these animals and this change correlates with the
behavioral deficits. It is interesting to note that an increase in body weight has been described
in R6/2 (at 8-9 weeks) despite high leptin levels. It was shown to precede a period
characterized by weight loss which begins at 12-13 weeks (Fain et al., 2001). HD patients
usually experience weight loss, despite an increased caloric intake (Beal, 2000). Therefore
hypoactivity observed in the YAC128 is probably due to the increased body weight.
Additional studies should be performed to definitely establish the effects of BDNF in HD
transgenic mice and determine whether it may alter some of the early and subtle changes
occurring in YAC128 animals. In particular, it would be interesting to assess the effect on
electrophysiological parameters, which have been identified as indicator of early
dysfunctionalities in YAC128 neurons (Zeron et al., 2004).
In the second set of experiments, we used the lentiviral-based model of HD (Régulier et al.,
2002). Rats overexpressing htt853-82Q developed a severe pathology at 3 months, which is
characterized by neuronal loss, striatal shrinkage and ventricle enlargement reminiscent of
advanced stages of HD. However, the delivery of BDNF did not prevent the striatal pathology
and inclusion formation. These negative results should, however, be carefully analyzed before
drawing any definitive conclusions on the relevance of BDNF for HD.
Long-term exposure to high doses of BDNF could induce a desensitization of the TrkB
receptor and a down-regulation of TrkB mRNA in vivo. Treatment with high doses of this
neurotrophin for extended periods may reduce responsiveness (Frank et al., 1996). In
Parkinson’s disease, the delivery of high GDNF doses was shown to induce a down-
regulation of tyrosine hydroxylase (Rosenblad et al., 2003). In our study, Western blot
analysis of Lv-mediated BDNF synthesis showed that BDNF expression was approximately
2-5 times higher than the endogenous protein. Preliminary data on AAV-mediated delivery of
BDNF in the striatum of HD transgenic mice indicate that the expression of high levels of
BDNF in the striatum of R6/1 mice is associated with mortality (20%) and behavioral
abnormalities (Rodriguez et al., 2004). Reducing BDNF expression eliminates these toxic
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effects and leads to an up-regulation of DARPP-32, CB1 and ppENK expression in the
striatum. In all cases, no improvements of the behavioral deficits were observed.
In YAC128 mice and in the Lv-based rat model, BDNF expression in the striatum was not
associated with side effects. It is still needs to be established whether this local and sustained
BDNF production has modified the expression and function of BDNF receptor subunits
Similarly, additional studies are required to determine the impact of BDNF on striatal markers
and neurogenesis.
To deliver BDNF, we have injected lentiviral vector directly into the striatum. The infected
neurons in the target region are producing and releasing BDNF, that diffusess into the
striatum. Physiologically, cortical afferents deliver BDNF to the striatum. However, as vesicle
transport and axonal trafficking are impaired by mutant huntingtin (Gauthier et al., 2004;
Trushina et al., 2004), the local delivery of this factor in the striatum should be able to
overcome this deficit. However, at this stage we can not exclude that a cortical delivery of
BDNF might be advantageous, as it more closely corresponds to the physiological situation.
Cortical Lv-injection could be performed in rodents to evaluate whether the site of BDNF
production has a major impact on its protective effect in HD models.
In conclusion, this last chapter highlighted the difficulty of testing neuroprotective approaches
in genetic animal models of HD when compared to in vitro or toxin-induced lesion HD
models. A better knowledge of the molecular mechanisms involved in HD and the
identification of more specific targets are needed for future therapeutic approaches.
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CONCLUSIONS AND PERSPECTIVES
The underlying mechanisms leading to the specific degeneration of striatal neurons in HD are
still largely unknown and no therapy is currently available for this fatal disease.
In this thesis, I first developed a cellular model of HD, in order to gain further insight into the
molecular pathways leading to cell death, and to identify potential therapeutic agents. The
originality of this new in vitro model is based on the combined use of primary neuronal
cultures and lentiviral vectors. As a result, the majority of neurons express mutant huntingtin
and a chronic progression of the pathology is observed. This model will therefore be
particularly useful to perform population analyses in primary neurons and to evaluate subtle
changes induced by mutant htt, such as electrophysiological abnormalities, gene
transcriptional alterations and biochemical changes, as well as factors that would interfere
with these primary events. Collaborations have recently been initiated to take advantage of the
versatility and reproducibility of this approach and to assess the implication of various
intracellular pathways in HD pathology. Biochemical analyses have, for example, highlighted
the importance of mitochondrial impairment and disease-modifier candidates have been
evaluated. Expanded polyglutamine-mediated transcriptional dysregulation has been
identified prior to neuronal death. A large set of gene expression changes have been
previously described in R6/2 transgenic mice. The new cellular model has highlighted that
cell-autonomous changes in gene expression prior to cell death are induced by mutant htt.
Intrinsically, models are simplifying a complex dynamic process and are therefore affected by
several limitations. In our cellular paradigm, the major differences compared to the human
pathology are: (i) the expression of a small N-terminal mutant huntingtin fragment, (ii) the
presence of two alleles of wild type rat htt, (iii) the time course, which is still short compared
to the human disease, and finally, (iv) the artificially simplified setting, which excludes all
contributions from other brain regions, such as the cortical glutamatergic input the
dopaminergic innervations and neurotrophic delivery which are believed to modulate the
disease. Therefore data gathered from a cell culture models have to be validated in vivo.
In the second part of the thesis, genetic rodent models of HD were used to validate therapeutic
approaches with two neurotrophic factors, CNTF and BDNF. The results obtained with lenti-
CNTF are encouraging with regard to both gene therapy approaches and the potential
beneficial effects of this molecule in HD patients. These preliminary results have shown the
feasibility of the approach and the lack of toxicity. However, additional studies are
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required to further test the effectiveness of neurotrophic factors in animal models of HD.
None of the therapeutic candidates identified so far in animal models of HD have been
successfully tested in HD patients. The most relevant animal models and endpoints for pre-
clinical evaluation of new therapy have, therefore, not yet been validated. R6/2 mice, which
have been extensively characterized, are still the standard in the field. These mice show
neuronal dysfunctions with little evidence of neuronal loss; they have been used to identify
disease modifiers. However, these animals manifest several peripheral symptoms that might
not be directly related to HD, rendering the assessment of therapeutic strategies more difficult.
Lentiviral-based rat models could be an interesting experimental paradigm to mimic late
stages of the disease, and be complementary to transgenic models, but the LV-based models,
are characterized by a local striatal expression of a mutant htt fragments which is
oversimplifying HD pathology. New HD animal models closely reproducing the disease
progression and neuronal death are therefore still needed. The emergence of transgenic
approaches based on lentiviral vectors could represent a good opportunity to combine the
advantages of both techniques and to develop animal models with severe pathologies in
different species including primates. This would open new perspectives for longitudinal
follow-up of HD pathology by imaging and for more elaborate behavioral analysis.
Delivery of trophic factors into the brain is challenging, in this thesis we took advantage of
viral vectors to locally delivery trophic factors into the striatum, but alternative delivery
methods including ex vivo gene therapy approaches and non-viral delivery systems have been
developed. A phase I clinical trial based on encapsulated genetically engineered cells
producing CNTF has demonstrated the feasibility and safety of the approach (Bloch et al.
2004). The administration of CNTF in the ventricle of HD patients was not associated with
side effects and a mild improvement in electrophysiological parameters was observed.
However, no clinical benefit based on UPDRS motor score was obtained, probably due to the
implantation of a single capsule in the ventricle, leading to a scarce diffusion of CNTF. The
heterogeneity in the survival of encapsulated cells and the periodical capsule replacement
every 6 months represent major disadvantages of this approach. Recently, intra-putaminal
GDNF delivery with a minipump in Parkinson’ s disease patients has shown encouraging
preliminary results, at least one year post-treatment (Gill et al., 2003). The results of the phase
II clinical study, however, did not meet the primary endpoints and four of thirty-four patients
developed GDNF-blocking antibodies. In addition, two monkeys that have received unilateral
intraputaminal GDNF developed “unusual cerebellar cortical pathology” as reported at the
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annual meeting of the American Neurological Association this year. These observations
confirm the need for long-term follow-up, as high doses of trophic factor could cause severe
damages.
The delivery of trophic factor is by far not the only conceivable therapy. Different strategies
have been applied to treat Huntington’s disease: rebuilding the brain is the challenge of a pilot
study performed on 5 HD patient in Créteil (France). The fetal neuronal transplants in the
striatum showed a clinical benefit, one year post-implant on 3/5 patients. Long-term
evaluations as well as a phase II clinical trial are currently evaluating this treatment on a
larger number of patients (Peschanski et al., 2004).
A consortium of research centers financed by the NIH is using different HD models to screen
compounds that have already been approved by the FDA. The hope is that if an agent will be
particularly promising, it can be rapidly used in large clinical trials, as these compounds have
already been characterized pharmaceutically. At the present time, the absence of overlap
between the different models makes this strategy questionable and therefore drugs which are
less tested, but biologically more relevant, should probably be reconsidered.
Finally, the results for the HIV-1-derived lentiviral vectors described in this thesis confirmed
the interest of this gene-delivery tool for post-mitotic cells, with regard to efficiency, long-
term expression and lack of toxicity. Lentiviral vectors are therefore particularly suitable for
experimental biology in the field of neuroscience. However, biosafety concerns have to be
considered for future clinical applications, as these vectors are derived from a devastating
disease, and the risk of recombination with wild-type HIV can not to be excluded. The recent
development of new generations of AAV vectors has brought a valid alternative to lentiviral
vectors. Moreover, different serotypes might be used to modulate cell tropisms, which opens
the possibility for a more specific targeting.
In conclusion, the combination of a primary culture and a lentiviral vector yielded a new
relevant model for HD research. The lentiviral delivery of trophic factor has shown the
efficiency and the potential of this approach but needs to be validated in other genetic animal
models. In particular, major efforts have to develop additional transgenic models are required.
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ABBREVIATIONS
3-NP 3-nitropropionic acid
aa amino acid
AAV adeno-assiciated virus
AD Alzheimer disease
ALS amyotrophic lateral sclerosis
BDNF brain-derived neurotrophic factor
CA150 co-activator 150
CAG cytosine adenine guanine
CBP c-AMP-response-element-binding protein
ChAT cholin acetyltransferase
CIP4 cdc42-interacting protein 4
CLC cardiotrophin-like cytokine
CLF cytokine-like factor-1
CNS central nervous system
CNTF ciliary neurotrophic factor
cPPT central polypurine tract
CT C-terminus
CtBP C-terminal-binding protein
DARPP-32 dopamine and cAMP regulated phosphoprotein
DNA deoxyribose nucleic acid
DRPLA dentatorubralpallidoluysian atrophy
EIAV equine infectious anemia virus
FACS fluorescence-activatedcell sorter
FIP2 for 14.7K interacting protein
FIV feline immunodeficiency virus
GABA gamma-amino butric acid
GFAP glial fibrillary acid protein
GFP green fluorescent protein
GPe external segment of the globus pallidus
GPi internal segment of the globus pallidus
Grb2 growth factor receptor-binding protein 2
HAP1 htt-associated protein 1
HAP40 htt-associated protein-40
HD Huntington’s disease
HIP1 htt-interacting protein-1
Hip1 htt-interacting protein-1
HIP-14 htt-interacting protein-14
Hippi Hip-1 protein interactor
HIV human immuno-deficiency virus
hsp104 heat shock protein 104 kDa
Hsp40 heat shock protein 40 kDa
Hsp70 heat shock protein 70 kDa
htt huntingtin
HYP-J htt yeast protein-J
IL-6 interleukin-6
LacZ lactamase
LIF leukemia inhibitory factor
LTR long terminal
Lv lentiviral vector
MAP-2 microtubule-associated protein 2
MSN medium sized spiny neurons
NADPH-d nicotinamide adenine dinucleotide phosphate-diaphorase
NMDA N-metyl-D-aspartate
N-CoR nuclear receptor co-repressor
NeuN neuronal nuclei
NF neurofilament
NGF nerve growth factor
NMDA N-methyl-D-aspartate
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NT N-terminus
P/CAF p300/CBP associated factor
PACSIN1 protein kinace C and casein substrate in neurones 1
PD Parkinson’s disease
PGK phosphoglycerate kinase
PKB protein kinase B
PNS peripherial nervous system
PRD proline rich domain
PSD-95 postsynaptic density-95
Q glutamine
QA quinolinic acid
RasGAP Ras GTPase activating protein
REST RE1-silencing transcription factor
RNA ribonucleic acid
S421 serin 421
SBMA spinobulbar muscular atgrophy
SC35 splicing component 35 kDa
SCA spinocerebellar ataxia
SCID sever combined immunodeficiency
SGK serum- and glucocorticoid-induced kinase
SH3GL3 SH3-containing Grb2-like protein 4
shRNA small harpin RNA
SIV simian immunodeficiency virus
SNc substantia nigra pars compacta
SNr substantia nigra pars reticulata
SOD superoxide dismutase
Sp1 specificity protein 1
STAT signal transducers and activators of transcription
STN subthalamic nucleus
TAFII-130 TATA-binding protein (TBP)-associated factor
TBP TATA box protein
TH Thyrosin Hydroxylase
Trk tyrosine kinase
TUNEL terminal deoxynucleotidyl transferase dUTP Nick-End Labeling
UCHL-1 ubiquitin carboxyl terminal hydrolase
UPP ubiquitin-proteasome pathway
VEGF vascular endothelial growth facto
VSV-G vesicular somatitis virus G-glycoprotein
WPRE woodchuck post-transcriptional regulatory element
WT wild type
YAC yeast artificial chromosome
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